US20170210825A1 - Monospecific and multispecific antibodies and method of use - Google Patents

Monospecific and multispecific antibodies and method of use Download PDF

Info

Publication number
US20170210825A1
US20170210825A1 US15/466,587 US201715466587A US2017210825A1 US 20170210825 A1 US20170210825 A1 US 20170210825A1 US 201715466587 A US201715466587 A US 201715466587A US 2017210825 A1 US2017210825 A1 US 2017210825A1
Authority
US
United States
Prior art keywords
antibody
protease
antibodies
seq
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/466,587
Inventor
Bing Liu
David Light
Zhuozhi Wang
Douglas Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40110987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20170210825(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Priority to US15/466,587 priority Critical patent/US20170210825A1/en
Publication of US20170210825A1 publication Critical patent/US20170210825A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A61K47/48384—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases.
  • these antibodies may be modified by protease cleavage.
  • Protease control or regulation may be provided by a protease site located in, for example, a linker.
  • protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.
  • An antibody may be directed against one or more different antigens or one or more different epitopes on the same antigen.
  • a bispecific antibody is directed against two different antigens or two different epitopes on the same antigen.
  • these antibodies have great potential for antibody-based diagnosis and for the treatment of various diseases and disorders such as cancer, infectious diseases, autoimmune diseases, and blood diseases.
  • bispecific antibodies can selectively stimulate and expand T lymphocytes (Wong, et al., J. Immunol 139:1369-1374, 1987; Wong, et al., Clin. Immunol. Immunopathol.
  • a bispecific antibody may be used as a substitute for Factor VIII to enhance enzymatic reaction (US Patent Application No. 2007/0041978) or to direct stem cells to the site of injury in patients with myocardial infarction (Lum, et al., Blood Cells Mol. Dis. 32:82-87, 2004).
  • Bispecific antibodies targeting tumor-associated antigens and toxic agents may be used in cancer therapy.
  • one arm of the bispecific antibody may be directed to a tumor-associated antigen such as Her2, EGF receptor, CD20, CD22, CD30, CD33, CD52, and CA-125, and the other arm of the bispecific antibody may target a toxin, drug, or cytokine. That is, bispecific antibodies may selectively direct toxic agents to tumor cells enhancing the efficacy of therapeutic antibodies and decreasing systemic toxicity.
  • toxin/drug examples include calicheamicin, doxorubicin, epirubicin, methotrexate, ricin A, saporin, gelonin, and vinca alkaloids, and cytokine examples include tumor necrosis factor alpha (TNF-alpha) and IL-2.
  • TNF-alpha tumor necrosis factor alpha
  • protease activation and inhibition of the coagulation cascade examples include protease activation and inhibition of the coagulation cascade (Butenas, et al., Biochemistry 67:3-12, 2002; Esmon, Chest, 124:26S-32S, 2003), protease activation of protease-activatable receptors (Coughlin, Arterioscler. Thromb. Vasc. Biol. 18:514-518, 1998), protease release of membrane associated cytokines (Amour, et al., FEBS Lett.
  • protease processing of prohormones in secretory vesicles (Moore, et al., Arch. Physiol. Biochem. 110:16-25, 2002), and protease processing of proproteins during secretion (Scamuffa, et al., FASEB J. 20:1954-1963, 2006).
  • Proteases are often expressed or located in a tissue-specific or tumor-specific manner and examples include the membrane serine protease corin in heart tissue (Yan, et al., Proc. Natl. Acad. Sci.
  • proteases expressed in the pancreas and released to the duodenum
  • specific cleavage of amino acid sequences by human proteases include thrombin (Chang, Eur. J. Biochem. 151:217-224,1985), factor Xa (Nagai, et al., Methods Enzymol. 153:461-481, 1987), furin (Brennan, et al., FEBS Lett. 347:80-84, 1994), subtilisin-like prohormone convertases (Lipkind, et al., J. Biol. Chem.
  • Protease cleavage is widely used in in vitro studies to specifically remove protein or peptide tags from recombinant proteins or to process hybrid recombinant proteins.
  • human rhinovirus 3C protease, thrombin, or factor Xa have been used to remove glutathione S-transferase (GST) tags (Dian, et al., Life Sciences News—Amersham Biosciences 10:1-5, 2002) and factor Xa has been use to process hybrid proteins (Nagai, et al., 1987).
  • GST glutathione S-transferase
  • Proteases are often targets for drugs as a means to regulate biological processes; and examples include factor Xa (Phillips, et al., J. Med. Chem.
  • Specific protease cleavage sites have been incorporated into linkers that link a toxin molecule to a targeting antibody in order to allow protease specific release of the toxin by intracellular proteases (Trail, et al., Cancer Immunol. Immunother. 52:328-337, 2003).
  • targeting antibodies have been created in many formats. For example, bispecific antibodies have been developed to allow binding to two different antigens or two different epitopes of an antigen by a single antibody molecule (Segal, et al., Curr. Opin. Immunol. 11:558-562, 1999; Tomlinson, et al., Methods Enzymol.
  • the present invention relates to a novel antibody format, for example, monospecifc and multispecific antibodies.
  • the antibodies of the present invention may be constructed by tandem linking of two different heavy chain (H) variable region domains (V H ) and two different light chain (L) variable region domains (V L ).
  • the heavy chain and light chain may form a Fab-like or IgG-like molecule through the disulfide bond between constant (C) regions.
  • Multispecific antibodies may be generated by linking more than two antibody variable domains.
  • the antibodies of the present invention may be modified by protease cleavage.
  • protease-regulated antibodies may be, for example, monospecific antibodies, bispecific antibodies, or antibodies with sequential binding-activity upon protease digestion in either, for example, Fab-like or IgG-like format.
  • Protease control or regulation may be provided by a protease site located in, for example, a linker.
  • protease-regulated antibodies may be utilized for the diagnosis and treatment of various diseases, and provide an additional level of control for biological drugs for therapeutic or diagnostic applications.
  • FIG. 1 Schematic drawing of a monospecific protease-regulated antibody with a linker which contains a protease site between variable domain and Fc domain (“Type 1”).
  • FIG. 2 Schematic drawing of a bispecific protease-regulated antibody with a linker which contains a protease cleavage sequence that allows removal of one antigen-binding site (“Type 2”).
  • FIG. 3 Schematic drawing of another bispecific protease-regulated antibody with a linker which contains a protease cleavage sequence that allows removal of one antigen-binding site (“Type 2”).
  • FIG. 4 Schematic drawing of the application of a bispecific protease-regulated antibody that simultaneously binds two different antigens.
  • FIG. 5 Schematic drawing of a protease-regulated antibody that cannot bind to two different antigens simultaneously (“Type 3”).
  • FIG. 6 Schematic drawing of the application of a protease-regulated antibody that cannot bind to two different antigens simultaneously.
  • FIG. 7 Schematic drawing of a monospecific protease-regulated antibody ‘prodrug’ that can only bind antigen following protease activation to remove inactive blocking antibody domains (“Type 4”).
  • FIG. 8 Map of an expression vector for an IgG-like bispecific antibody.
  • SignalP signal peptide
  • VLam3E10 variable region of 3E10 lambda chain
  • Vk19G9 variable region of 19G9 kappa chain
  • C kappa constant region of kappa chain
  • DHFR dihydrofolate reductase
  • V H variable region of heavy chain
  • Neo neomycin resistant gene
  • 3E10VH variable region of 3E10 heavy chain
  • 19G9VH variable region of 19G9 heavy chain
  • CH constant region of heavy chain
  • Amp ampicillin resistant gene.
  • FIG. 9 Map of expression vector of Fab-like bispecific antibody. LacZ, lac Z promoter; ompA and pho A, signal peptide; VL-linkl-VK, variable region of light chain of bispecific antibody against tissue factor and RG1; CL-kappa, constant region of kappa chain; VHs with linker, variable region of heavy chain of bispecific antibody against tissue factor and RG1; CH1, the first constant region of IgG heavy chain; cat, chloramphenicol resistant gene.
  • FIG. 10 TF-binding ELISA.
  • Four bispecific antibodies and parental antibodies were analyzed for binding to TF.
  • Antibodies were detected with HRP-conjugated anti-human IgG was used for detection.
  • Curve fitting of the data was performed using a 4-parameter equation with the Solver function in Microsoft Excel.
  • FIG. 11 RG1-binding ELISA.
  • a bispecific antibody containing Linker 1, anti-RGI antibody 19G9, and polyclonal nonimmune control human IgG kappa were analyzed for binding to RG-1. Curve fitting of the data was performed using a 4-parameter equation with the Solver function in Microsoft Excel.
  • Positive control anti-RG1 IgG 19G9: IC 50 1.4 nM (filled diamond, solid line);
  • Linker 1 (SEQ ID NO: 1) IgG-like bispecific antibody: IC 50 1.1 nM (filled triangle, large dashed line); and negative control nonimmune polyclonal human IgG kappa: no binding (open triangle, small dashed line).
  • FIG. 12 Measurement of the antigen-binding activity of a bispecific protease-regulated antibody using a sandwich antigen-binding ELISA.
  • the linker of this antibody contained cleavage sites for enterokinase.
  • FIG. 13 Measurement of the antigen-binding activity of protease-regulated antibodies 3E10-Typel-Fab and 19G9-Typel-Fab.
  • the controls are designated 3E10-Reg-Fab, 19G9-Reg-Fab, and HuFab.
  • FIG. 14 Measurement of the antigen-binding activity of Fab-like protease-regulated antibodies H1L1, H1L4, H1L7, H14L7, and H5L5 (Type 2) in the absence and presence of enterokinase.
  • Parental antibodies 3E10 and 19G9, and polyclonal human Fab were used as control.
  • FIG. 15 Measurement of the antigen-binding activity of Fab-like protease-regulated antibodies H2L1, H2L2, and H2L8 (Type 3) and H3L1, H3L4, and H5L4 (Type 4) in the absence and presence of enterokinase.
  • Parental antibodies 3E10 and 19G9, and polyclonal human Fab were used as control.
  • FIG. 16 Western blots of protease-regulated antibody 3E10-Type1-Fab detected with anti-Myc antibody (A) or anti-kappa chain antibody (B). Lane 1 and 2: 3E10-Typel-Fab without or with enterokinase digestion, respectively. Lane 3 and 4: 3E10-Reg-Fab without or with enterokinase digestion, respectively.
  • FIG. 17 Western blots of Fab-like protease-regulated antibodies H1L1, H1L7, and H5L5 (Type 2) in the absence and presence of enterokinase. Antibodies were detected with anti-IgG(H+L) antibody. Lane 1 and 2: H1L1 without or with enterokinase digestion, respectively. Lane 3 and 4: H1L7 without or with enterokinase digestion, respectively. Lane 5 and 6: H5L5 without or with enterokinase digestion, respectively. Lane 7: 3E10-Reg-Fab.
  • FIG. 18 Western blots of Fab-like protease-regulated antibodies H2L2 and H2L8 (Type 3) and H3L4 (Type 4) in the absence and presence of enterokinase. Antibodies were detected with anti-Myc antibody. Lane 1 and 2: H2L2 without or with enterokinase digestion, respectively. Lane 3 and 4: H2L8 without or with enterokinase digestion, respectively. Lane 5 and 6: H3L4 without or with enterokinase digestion, respectively.
  • Antibody as used herein includes intact immunoglobulin molecules (e.g., IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA), as well as fragments thereof, such as Fab, F(ab′) 2 , scFv, Fv, and diabody which are capable of specific binding to an epitope of a protein.
  • the term antibody also extends to other protein scaffolds that are able to orient antibody complementarity-determining region (CDR) inserts into the same active binding conformation as that found in natural antibodies such that the binding to the target antigen observed with these chimeric proteins is maintained relative to the binding activity of the natural antibody from which the CDRs were derived.
  • CDR complementarity-determining region
  • Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or variable domain thereof.
  • Examples of antibody fragments include Fab, Fab′, F(ab′) 2 , and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; monospecific antibodies; bispecific antibodies; and multispecific antibodies formed from antibody fragments.
  • autoimmune diseases includes, but is not limited to, multiple sclerosis, rheumatoid arthritis, lupus, type I diabetes mellitus, Crohn's disease, autoimmune hemolytic anemia, autoimmune hepatitis, glomerulonephritis, inflammatory bowel disease, myocarditis, psoriasis, thyroiditis, ulcerative colitis, and Graves'disease.
  • biological sample or “patient sample” as used herein, refers to a sample obtained from an organism or from components (e.g., cells) of an organism.
  • the sample may be of any biological tissue or fluid.
  • the sample may be a “clinical sample” which is a sample derived from a patient.
  • Such samples include, but are not limited to, sputum, blood, serum, plasma, blood cells (e.g., white cells), tissue samples, biopsy samples, urine, peritoneal fluid, and pleural fluid, saliva, semen, breast exudate, cerebrospinal fluid, tears, mucous, lymph, cytosols, ascites, amniotic fluid, bladder washes, and bronchioalveolar lavages or cells therefrom, among other body fluid samples.
  • the patient samples may be fresh or frozen, and may be treated with heparin, citrate, or EDTA.
  • Biological samples may also include sections of tissues such as frozen sections taken for histological purposes.
  • cancer includes, but is not limited to, solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, and their distant metastases.
  • solid tumors such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, and their distant metastases.
  • lymphomas sarcomas, and leukemias.
  • conjugate refers to an antibody chemically linked to a chemical moiety, such as a therapeutic or cytotoxic agent.
  • infectious diseases includes, but is not limited to, HIV/AIDS, lower respiratory infections, diarrheal diseases, tuberculosis, malaria, measles, pertussis, tetanus, meningitis, syphilis, hepatitis B and tropical diseases.
  • linker refers to a peptide (or polypeptide) comprising two or more amino acid residues joined by peptide bonds and used to link one or more antibody domains.
  • the linker may contain one or more protease cleavage sites.
  • proteases refers to any enzyme, including the endopeptidases and exopeptidases, which catalyze the hydrolytic breakdown of proteins into peptides or amino acids.
  • the present invention is directed to the design and production of monospecific, bispecific antibodies, and multispecific antibodies.
  • the bispecific antibodies and multispecific antibodies may comprise tandem linked V H a-V H b-V H c . . . C H in one polypeptide and V L a-V L b-V L c . . . C L in another polypeptide.
  • the V H and V L domains may be exchanged from one polypeptide to another to create polypeptides such as V H a-V L b-V H c . . . C H and V L a-V H b-V L c . . . C L .
  • the two polypeptides may form ⁇ immers in the Fab format or the half IgG-like format, or two of each polypeptide may form a four polypeptide-containing homodimer of the IgG-like format.
  • These bispecific or multispecific antibodies or antibody fragments thereof may simultaneously bind different antigens or different epitopes of the same antigen.
  • a recombinant IgG-like bispecific antibody may be constructed by the tandem linking of two different V H domains of a heavy chain and two different V L domains of a light chain.
  • the construct is exemplified as follows:
  • Another bispecific antibody may comprise the following:
  • the present invention also relates to protease-regulated antibodies.
  • Protease-regulated antibodies may be, for example, monospecific antibodies, bispecific antibodies, multispecific antibodies, or antibodies with sequential binding-activity upon protease digestion in either, for example, Fab-like or IgG-like format.
  • Protease control or regulation may be provided by a selective protease site located in, for example, a linker.
  • These protease-regulated antibodies may be utilized for the diagnosis and treatment of various diseases including but not limited to cancer, infectious disease, and autoimmune diseases, and provide an additional level of control for biological drugs for therapeutic or diagnostic applications.
  • Protease-regulated antibodies may comprise a heavy chain (H) variable domain (V H )-linker-heavy chain constant domain (CH) in one polypeptide and a light chain (L) variable domain (V L )-linker-light chain constant domain (CL) in another polypeptide.
  • Bispecific protease-regulated antibodies may comprise, for example, V H1 -linker-V H2 -CH in one polypeptide and V L1 -linker-V L2 -CL in another polypeptide, both regulated by proteolytic cleavage of the linker.
  • V H and V L domains in the bispecific protease-regulated antibodies may be exchanged from one polypeptide to another polypeptide to create polypeptides such as, for example, V H1 -linker-V L2 -CH and V L1 -linker-V H2 -CL.
  • the two polypeptides may form ⁇ immers, for example, in a Fab-like format, a half-IgG-like format, or an IgG-like format (e.g., two of each polypeptide forming a four polypeptide-containing homodimer).
  • the bispecific and sequential protease-regulated antibodies or antibody fragments may (1) simultaneously bind two different antigens or different epitopes of the same antigen, (2) sequentially bind two different antigens or different epitopes on the same antigen in a manner that may be dependent on the length, adjacent sequence, and design of the linker, or (3) a monospecific protease-activated binder which is in latent or prodrug form prior to protease digestion and which is switched on by protease cleavage.
  • protease-regulated antibodies are described herein whereby antibody formats are designed with selectivity due to specific protease-dependent binding or protease-specific functionality.
  • these protease-regulated antibodies may be described by deletions and/or additions of antibody framework, location of the linker, and its properties including length and solvent accessibility.
  • the linker may contain a cleavage site specific for a protease found in a target cell or tissue.
  • a protease-regulated antibody may contain a protease site in a linker located between the variable domain and the constant region domain and this antibody may bind only one antigen as illustrated in FIG. 1 (“Type 1”).
  • protease-regulated antibody may simultaneously bind two different antigens or two different epitopes as shown in FIGS. 2 and 3 (“Type 2”) in the absence of a protease.
  • the first V H /V L domains of this antibody bind to an antigen without blocking the second V H /N L domains from binding to a second antigen.
  • This antibody can bind to antigens without steric blocking of the CDR regions of the second variable domains.
  • the simultaneous binding of this protease-regulated antibody to both antigens is prevented by proteolytic cleavage. That is, when the linker is cleaved by a protease, the antibody can only bind to the second antigen or separately bind two antigens. Simultaneous antigen binding is important for antibody function, for example, in cross-linking receptors, which may be prevented by proteolytic cleavage. Thus, an additional degree of specificity is added by including a protease site in the linker.
  • This bispecific protease-regulated antibody is more selective than a monospecific antibody because this antibody will specifically target cells or tissues expressing both antigens.
  • the additional degree of specificity is provided by the specific protease site in the linker.
  • Cell A and Cell B express both Antigen 1 and Antigen 2, however only Cell B expresses the selective protease.
  • the bispecific protease-regulated antibody with the uncleavable linker i.e., this linker does not contain the protease cleavage site
  • the bispecific protease-regulated antibody will bind to Cell B with lower avidity because the Antigen 1 binding domain is removed by proteolytic cleavage of the linker by the selective protease expressed by Cell B (alternately, the selective protease may be expressed by adjacent cells localized in the same tissue as Cell B).
  • FIG. 5 illustrates a protease-regulated antibody that may sequentially bind to each antigen in a protease-dependent manner. That is, prior to protease cleavage of the linker, the protease-regulated antibody binds to a first antigen and following protease cleavage, the antibody binds to a second antigen (“Type 3”).
  • the V H /V L domains of the N-terminal antibody bind to an antigen, but block the CDR regions of the downstream V H /V L domains from binding to a second antigen.
  • Protease cleavage of the linker allows removal of the N-terminal antibody, and removing the N-terminal antibody domains then permits binding to a second antigen. This allows for greater cell and/or tissue selectivity by requiring sequential binding.
  • Cell A and Cell B express both Antigen 1 and Antigen 2, but only Cell B expresses the selective protease.
  • Antigen 2 is a cell surface receptor that internalizes into the cell and allows internalization of antibodies that bind to it.
  • the protease-regulated antibody will bind to Antigen 1 expressed by Cell A and Cell B. However, only Cell B expresses the selective protease (or possibly cells adjacent to Cell B in the same tissue).
  • the protease-regulated antibody will be activated by proteolytic cleavage and internalized via Antigen 2 expressed on Cell B. Thus, this protease-regulated antibody will be specifically internalized by cells expressing Antigen 1, Antigen 2, and the selective protease.
  • a protease-regulated antibody may not bind to an antigen before protease digestion, but may bind to antigen following protease digestion (“Type 4”).
  • Type 4 An example of this antibody is illustrated in FIG. 7 .
  • This monospecific protease-regulated antibody also contains a protease cleavage linker that allows removal of the N-terminal non-functional antibody which then leads to binding to an antigen by the functional antibody domains that are thus exposed.
  • Type 4 protease-regulated antibodies may be created by three approaches. In the first approach the protease cleavable linker sequence is modified so that it prevents the N-terminal V H and V L domains of a Type HI antibody (V H 1 and V L 1) from binding to the first antigen.
  • linkers utilized in Type III antibodies shown in Tables 6 and 7 are now combined with heterodimeric N-terminal V H and V L domains that have been mutated to destroy their antigen binding function. Examples of this approach are shown in the sequences in Table 9 in which the CDR3 of V H 1 and CDR3 of V L 1 are replaced by a poly-alanine sequence of a similar length as the respective CDR.
  • the linkers utilized in Type III antibodies shown in Tables 6 and 7 are combined with homodimeric N-terminal domains derived from the constant regions of antibodies.
  • the complete V H 1 and V L 1 domains of a Type III antibody are both replaced by the same constant domain that is capable of heterodimerization, for example, the CH3 domain of IgG or the CH4 domain of IgE.
  • protease-regulated antibodies may be modified by protease cleavage of the linker as described below.
  • the protease-regulated antibody illustrated in FIG. 1 (Type 1) contains a protease site in the linker between the antigen binding domains and the Fc domain. This antibody will specifically target cells or tissues that present the antigen. When the linker is cleaved by the protease, the resultant protease-regulated antibody releases the functional Fc portion. In tissues where the protease is present, this antibody will release the Fc portion which is essential to antigen crosslinking, and induce an immune response such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement-dependent cytotoxicity
  • hepsin a serine protease
  • the antibody In a cancer patient treated with a protease-regulated antibody against hepsin, the antibody would attack the tumor cells via the Fc portion-induced ADCC and CDC. However, in the liver, the protease-regulated antibody would initially bind to hepsin, but the Fc portion would be cleaved by a liver-specific protease prior to initiation of ADCC or CDC preventing liver toxicity.
  • the peptide (or polypeptide) linker of the protease-regulated antibody may comprise two or more amino acid residues and may contain one or more protease cleavage sites.
  • the linkers may alter antibody conformation, stability, and antigen-binding activities.
  • the length of linkers may range, for example, from 0 to about 100 amino acid residues. The following are examples of linkers:
  • Linker 1 SDDDDK (SEQ ID NO: 2)
  • Linker 2 GGGGSDDDDK (SEQ ID NO: 3)
  • Linker 3 GGGGSDDDDKGGGGS (SEQ ID NO: 4)
  • Linker 4 GGGGSGGGGSGGGGS (SEQ ID NO: 5)
  • Linker 5 IHPVLSGLSRIVNGEDAVPG (SEQ ID NO: 6)
  • Linker 6 VAAPFDDDDKIVGGYICEEN (SEQ ID NO: 7)
  • Linker 7 ELLESYIDGRIVEGSDAEIG (SEQ ID NO: 8)
  • Linker 8 STQSFNDFTRVVGGEDAKPG (SEQ ID NO: 9)
  • Linker 9 PERGDNNLTRIVGGQECKDG (SEQ ID NO: 10)
  • Linker 10 EDQEDQVDPRLIDGKMTRRG (SEQ ID NO: 11)
  • Linker 11 KRNASKPQGRIVGGKVCPKG (SEQ ID NO: 12)
  • Linker 12 S
  • Table 1 illustrates the excision site of several proteases.
  • ADAM metallopeptidase domain 9 (meltrin gamma) ADAM metallopeptidase domain 10
  • ADAM metallopeptidase domain 17 (TNFalpha, converting enzyme)
  • ADAM metallopeptidase domain 28 ADAM-like, decysin 1 ADAM metallopeptidase, thrombospondin type 1 motif 1 ADAM metallopeptidase, thrombospondin type 1 motif 5, aggrecanase-2 ADAMTS-like 3 ADAMTS-like 4
  • Beta-site APP-cleaving enzyme 1 Bleomycin hydrolase Bone morphogenetic protein 1 Complement component 1, r subcomponent Complement component 1, s subcomponent Calpain 2, (m/II) large subunit Caspase 1, apoptosis-related cysteine peptidase (Th-1 ⁇ convertase) Caspase 2, apoptosis-
  • the protease-regulated antibodies of the present invention may bind one or more antigens.
  • antigens may be selected from the group consisting of cytokines, cell surface receptors, enzymes, and receptors. These antigens include, but are not limited to, CD3, CD4, CD8, CD20, CD25, CD28, CD33, CD52, IL-2, IL-7, IL-8, TNF-alpha, TGF-beta INF-beta, INF-gamma, GMCSF, GCSF, VEGF, C5, EpCAM, EGF receptor, CD2 receptor, IL 2 receptor, IgE receptor, intergrin, and MHC class II.
  • the antibodies of the present invention may be utilized for the diagnosis and therapy of various diseases. For example, antibodies directed against human immunological cells and tumor-associated antigen may be used for cancer therapy. These antibodies may also be directed against tumor-associated antigen and toxic agents or enzymes for use as a cancer therapeutic.
  • the antibodies of the present invention may also be utilized for the treatment of hemophilia and thrombosis as well as stem cell transplantation. These antibodies may be used for the selective stimulation and expansion of lymphocyte subset. In addition, these antibodies may used for the detection of disease-related antigens.
  • bispecific antibodies may be used to recruit the immune system to attach tumor cells.
  • Targets on immunological cells include, but are not limited to, CD3, CD8, and Fc receptor.
  • Tumor-associated antigens include, but are not limited to, Her2, EGF receptor, CD20, CA-125, and carcinoembryonic antigen (CEA).
  • CEA carcinoembryonic antigen
  • a bispecific antibody against CD8 and Her2 can direct CD8-expressing cytotoxic lymphocytes to attack Her2 expressing breast cancer cells.
  • the antibodies or antibody fragments of the invention, or compositions including the antibodies or fragments can include a cytoxic agent that is conjugated to the antibody or fragment.
  • the cytotoxic agent is monomethylauristatin-E (MMAE), however, other cytoxic agents are also provided, which can include, for example, functional analogs of MMAE (e.g.
  • cytotoxic agents e.g., aplidin, azaribine, anastrozole, azacytidine, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, 10-hydroxycamptothecin, carmustine, celebrex, chlorambucil, cisplatin, irinotecan (CPT-I 1), SN-38, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, ethinyl estradiol, estramustine, etoposide,
  • phage-antibody technology may be used to generate antibodies (Knappik, et al., J. Mol. Biol. 296:57-86, 2000).
  • Another approach for obtaining antibodies is to screen a DNA library from B cells as described by Dower, et al., (WO 91/17271) and McCafferty, et al., (WO 92/01047).
  • libraries of phage are produced in which members display different antibodies on their outer surfaces.
  • Antibodies are usually displayed as Fv or Fab fragments. Phage displaying antibodies are selected by affinity enrichment for binding to a selected protein.
  • Antibodies may also be produced using trioma methodology (Oestberg, et al., Hybridoma 2:361-367, 1983; U.S. Pat. No. 4,634,664; U.S. Pat. No. 4,634,666).
  • Antibodies may also be purified from any cell that expresses the antibodies, including host cells that have been transfected with antibody-encoding expression constructs.
  • the host cells may be cultured under conditions whereby the antibodies are expressed.
  • Purified antibody may be separated from other cellular components that may associate with the antibody in the cell, such as certain proteins, carbohydrates, or lipids using methods well known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis. Purity of the preparations may be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.
  • a preparation of purified antibodies may contain more than one type of antibody.
  • antibodies may be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (see, e.g., Merrifield, J. Am. Chem. Soc. 85:2149-2154, 1963; Roberge, et al., Science 269:202-204, 1995). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer).
  • fragments of antibodies may be separately synthesized and combined using chemical methods to produce a full-length molecule.
  • the antibodies of the present invention may be generated from parental antibodies.
  • Parent antibodies may be selected from various antibodies capable of binding specific targets and well known in the art, such as, but not limited to, but are not limited to anti-TNF antibody, anti-IL-12 antibody; anti-IL-18 antibody, anti-C5, anti-CD147, anti-gp120, anti-CD11a, anti-CD18, anti-VEGF, anti-CD40L, anti-ICAM-1, anti-CD2, anti-EGFR, anti-TGF-beta 2, anti-E-selectin, anti-Her2/neu, anti-CD14, anti-ICAM-3, anti-CD80, anti-CD4, anti-CD3, anti-CD23, anti-beta2-integrin, anti-CD52, anti-CD22, anti-CD20, anti-CD25, anti-CD33, anti-HLA, anti-IL-1alpha, anti-IL-1, anti-IL-1 receptor, anti-IL-2 receptor, anti-IL-4, anti-IL4 receptor, anti-IL5, anti-IL-5 receptor
  • Parent antibodies may also be selected from various therapeutic antibodies including, but are not limited to, rituximab, trastuzumab, pertuzumab, cetuximab, alemtuzumab, muromonab, ibritumomab, gemtuzumab ozogamicin, alefacept, abciximab, basiliximab, palivizumab, infliximab, adalimumab, etanercept, natalizumab, bevacizumab, omalizumab, efalizumab, clenoliximab, labetuzumab, epratuzumab, and visilizumab.
  • trastuzumab pertuzumab
  • cetuximab cetuximab
  • alemtuzumab muromonab
  • ibritumomab gemtuzumab ozogamicin
  • the newly synthesized molecules may be substantially purified by preparative high performance liquid chromatography (see, e.g., Creighton, Proteins: Structures and Molecular Principles , WH Freeman and Co., New York, N.Y., 1983).
  • the composition of a synthetic polypeptide may be confirmed by amino acid analysis or sequencing (e.g., using Edman degradation).
  • the present invention also relates to bispecific or bifunctional antibodies that have one binding site that specifically binds to a first antigen and a second binding site that specifically binds to a second antigen. This results in multi-functional valency, that is, an ability to bind at least two different epitopes simultaneously.
  • the present invention also relates to polynucleotides encoding antibodies. These polynucleotides may be used, for example, to produce quantities of the antibodies for therapeutic or diagnostic use.
  • Polynucleotides of the present invention may also be isolated from host cells, free of other cellular components such as membrane components, proteins, and lipids.
  • Polynucleotides may be isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide may be used to obtain isolated polynucleotides encoding antibodies of the invention. For example, restriction enzymes and probes may be used to isolate polynucleotides which encode antibodies.
  • Antibody-encoding cDNA molecules may be made with standard molecular biology techniques, using mRNA as a template. Thereafter, cDNA molecules may be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook, et al., ( Molecular Cloning: A Laboratory Manual , (Second Edition, Cold Spring Harbor Laboratory Press; Cold Spring Harbor, N.Y.; 1989) Vol. 1-3). An amplification technique, such as PCR, may be used to obtain additional copies of the polynucleotides. Alternatively, synthetic chemistry techniques may be used to synthesize polynucleotides encoding antibodies of the invention.
  • the polynucleotide may be inserted into an expression vector that contains the necessary elements for the transcription and translation of the inserted coding sequence.
  • Methods that are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding antibodies and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook, et al. (1989) and in Ausubel, et al., ( Current Protocols in Molecular Biology , John Wiley & Sons, New York, N.Y., 1995).
  • a variety of expression vector/host systems may be utilized to contain and express sequences encoding antibodies. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV); or bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.
  • microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors
  • yeast transformed with yeast expression vectors insect cell systems infected with virus expression vectors (e.g., baculovirus)
  • plant cell systems transformed with virus expression vectors e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, T
  • control elements or regulatory sequences are those non-translated regions of the vector—enhancers, promoters, 5′ and 3′ untranslated regions—which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters can be used. The baculovirus polyhedrin promoter may be used in insect cells.
  • Promoters or enhancers derived from the genomes of plant cells may be cloned into the vector.
  • plant viruses e.g., viral promoters or leader sequences
  • promoters from mammalian genes or from mammalian viruses may be used. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding an antibody, vectors based on SV40 or EBV may be used with an appropriate selectable marker.
  • the affinity (K d ) of antibody binding to an antigen may be assayed using any method known in the art including, for example, immunoassays such as enzyme-linked immunospecific assay (ELISA), Bimolecular Interaction Analysis (BIA) (see, e.g., Sjolander and Urbaniczky, Anal. Chem. 63:2338-2345, 1991; Szabo, et al., Curr. Opin. Struct. Biol. 5:699-705, 1995), and fluorescence-activated cell sorting (FACS) for quantification of antibody binding to cells that express an antigen.
  • immunoassays such as enzyme-linked immunospecific assay (ELISA), Bimolecular Interaction Analysis (BIA) (see, e.g., Sjolander and Urbaniczky, Anal. Chem. 63:2338-2345, 1991; Szabo, et al., Curr. Opin. Struct. Biol. 5:699-705, 1995
  • BIA is a technology for analyzing biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcoreTM). Changes in the optical phenomenon surface plasmon resonance (SPR) may be used as an indication of real-time reactions between biological molecules.
  • SPR surface plasmon resonance
  • the present invention also relates to the use of quantitative immunoassays to measure levels of proteins in patient samples.
  • Many formats may be adapted for use with the methods of the present invention.
  • the detection and quantitation of a protein in patient samples may be performed, by enzyme-linked immunosorbent assays, radioimmunoassays, dual antibody sandwich assays, agglutination assays, fluorescent immunoassays, immunoelectron and scanning microscopy, among other assays commonly known in the art.
  • the quantitation of a protein in such assays may be adapted by conventional methods known in the art.
  • Serial changes in circulating a protein levels may be detected and quantified by a sandwich assay in which the capture antibody has been immobilized using conventional techniques on the surface of the support.
  • Suitable supports include, for example, synthetic polymer supports, such as polypropylene, polystyrene, substituted polystyrene, polyacrylamides (such as polyamides and polyvinylchloride), glass beads, agarose, and nitrocellulose.
  • synthetic polymer supports such as polypropylene, polystyrene, substituted polystyrene, polyacrylamides (such as polyamides and polyvinylchloride), glass beads, agarose, and nitrocellulose.
  • the antibodies useful to identify proteins may be labeled in any conventional manner.
  • An example of a label is horseradish peroxidase, and an example of a method of labeling antibodies is by using biotin-strepavidin complexes.
  • antibodies used in the immunoassays of this invention that are used as tracers may be labeled in any manner, directly or indirectly, that results in a signal that is visible or can be rendered visible.
  • Detectable marker substances include radionuclides, such as 3 H, 125 I, and 131 I; fluorescers, such as, fluorescein isothiocyanate and other fluorochromes, phycobiliproteins, phycoerythin, rare earth chelates, Texas red, dansyl and rhodamine; colorimetric reagents (chromogens); electron-opaque materials, such as colloidal gold; bioluminescers; chemiluminescers; dyes; enzymes, such as, horseradish peroxidase, alkaline phosphatases, glucose oxidase, glucose-6-phosphate dehydrogenase, acetylcholinesterase, alpha-, beta-galactosidase, among others; coenzymes;
  • Another detection and quantitation systems produce luminescent signals, bioluminescent (BL) or chemiluminescent (CL).
  • chemiluminescent (CL) or bioluminescent (BL) assays the intensity or the total light emission is measured and related to the concentration of the unknown analyte.
  • Light can be measured quantitatively using a luminometer (photomultiplier tube as the detector) or charge-coupled device, or qualitatively by means of photographic or X-ray film.
  • the main advantages of using such assays is their simplicity and analytical sensitivity, enabling the detection and/or quantitation of very small amounts of analyte.
  • luminescent labels are acridinium esters, acridinium sulfonyl carboxamides, luminol, umbelliferone, isoluminol derivatives, photoproteins, such as aequorin, and luciferases from fireflies, marine bacteria, Vargulla and Renilla .
  • Luminol can be used optionally with an enhancer molecule such as 4-iodophenol or 4-hydroxy-cinnamic acid.
  • a CL signal is generated by treatment with an oxidant under basic conditions.
  • Additional luminescent detection systems are those wherein the signal (detectable marker) is produced by an enzymatic reaction upon a substrate.
  • CL and BL detection schemes have been developed for assaying alkaline phosphatases (AP), glucose oxidase, glucose 6-phosphate dehydrogenase, horseradish peroxidase (HRP), and xanthine-oxidase labels, among others.
  • AP and HRP are two enzyme labels which can be quantitated by a range of CL and BL reactions.
  • AP can be used with a substrate, such as an adamantyl 1,2-dioxetane aryl phosphate substrate (e.g. AMPPD or CSPD; Kricka, L.
  • HRP is may be used with substrates, such as, 2′,3′,6′-trifluorophenyl-methoxy-10-methylacridan-9-carboxylate.
  • CL and BL reactions may be adapted for analysis not only of enzymes, but also of other substrates, cofactors, inhibitors, metal ions, and the like.
  • luminol, firefly luciferase, and marine bacterial luciferase reactions are indicator reactions for the production or consumption of peroxide, ATP, and NADPH, respectively. They may be coupled to other reactions involving oxidases, kinases, and dehydrogenases, and may be used to measure any component of the coupled reaction (enzyme, substrate, cofactor).
  • the detectable marker may be directly or indirectly linked to an antibody used in an assay of this invention.
  • exemplary of an indirect linkage of the detectable label is the use of a binding pair between an antibody and a marker or the use of a signal amplification system.
  • binding pairs that may be used to link antibodies to detectable markers are biotin/avidin, streptavidin, or anti-biotin; avidin/anti-avidin; thyroxine/thyroxine-binding globulin; antigen/antibody; antibody/ anti-antibody; carbohydrate/lectins; hapten/anti-hapten antibody; dyes and hydrophobic molecules/hydrophobic protein binding sites; enzyme inhibitor, coenzyme or cofactor/enzyme; polynucleic acid/homologous polynucleic acid sequence; fluorescein/anti-fluorescein; dinitrophenol/anti-dinitrophenol; vitamin B12/intrinsic factor; cortisone, cortisol/cortisol binding protein; and ligands for specific receptor protein/membrane associated specific receptor proteins.
  • labels may be bound either covalently or non-covalently.
  • Exemplary antibody conjugation methods are described in Avarmeas, et al., Scan. J. Immunol. 8(Suppl. 7): 7, 1978); Bayer, et al., Meth. Enzymol. 62:308, 1979; Chandler, et al., J. Immunol. Meth. 53:187, 1982; Ekeke and Abuknesha, J. Steroid Biochem. 11:1579, 1979; Engvall and Perlmann, J. Immunol. 109:129, 1972; Geoghegan, et al., Immunol. Comm. 7:1, 1978; and Wilson and Nakane, Immunofluorescence and Related Techniques , Elsevier/North Holland Biomedical Press; Amsterdam (1978).
  • a fluorescent, chemiluminescent, or colored product may be determined or measured fluorometrically, luminometrically, spectrophotometrically, or visually.
  • chemiluminescent compounds having an acridinium, benzacridinium, or acridan type of heterocyclic ring systems are other examples of labels.
  • acridinium esters include those compounds having heterocyclic rings or ring systems that contain the heteroatom in a positive oxidation state including such ring systems as acridinium, benz[a]acridinium, benz[c]acridinium, benz[c]acridinium, a benzimidazole cation, quinolinium, isoquinolinium, quinolizinium, a cyclic substituted quinolinium, phenanthridinium, and quinoxalinium.
  • the tracer may be prepared by attaching to the selected antibody either directly or indirectly a reactive functional group present on the acridinium or benzacridinium ester, as is well known to those skilled in the art (see, e.g., Weeks, et al., Clin. Chem. 29(8):1474-1479, 1983).
  • a reactive functional group present on the acridinium or benzacridinium ester
  • Examples of compounds are acridinium and benzacridinium esters with an aryl ring leaving group and the reactive functional group present in either the para or the meta position of the aryl ring. (see, e.g., U.S. Pat. No. 4,745,181 and WO 94/21823).
  • treatment includes any process, action, application, therapy, or the like, wherein a subject (or patient), including a human being, is provided medical aid with the object of improving the subject's condition, directly or indirectly, or slowing the progression of a condition or disorder in the subject.
  • combination therapy means the administration of two or more therapeutic agents to treat a disease, condition, and/or disorder.
  • administration encompasses co-administration of two or more therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each inhibitor agent.
  • administration encompasses use of each type of therapeutic agent in a sequential manner.
  • the antibodies of the inventin may be administered in combination with the following agents: cytotoxic agent, angiogenesis inhibitors, antirheumatic agent, muscle relaxant, narcotic, non-steroid anti-inflammatory drug, analgesic, anesthetic, sedative, local anesthetic, neuromuscular blocker, antimicrobial agent, immunoglobulins, antidepressant, asthma medication, cytokine, and cytokine antagonist.
  • agents cytotoxic agent, angiogenesis inhibitors, antirheumatic agent, muscle relaxant, narcotic, non-steroid anti-inflammatory drug, analgesic, anesthetic, sedative, local anesthetic, neuromuscular blocker, antimicrobial agent, immunoglobulins, antidepressant, asthma medication, cytokine, and cytokine antagonist.
  • the antibodies of the inventin may be administered in combination with various anti-cancer agents including, but not limited to, bleomycin, docetaxel, doxorubicin, edatrexate, erlotinib, etoposide, finasteride, flutamide, gemcitabine, genitinib, goserelin acetate, granisetron, imatinib, irinotecan, ondansetron, paclitaxel, pegaspargase, pilocarpine hydrochloride, porfimer sodium, interleukin-2, rituximab, topotecan, trastuzumab, triapine, vincristine, and vinorelbine tartrate, or therapeutic antibodies or fragments thereof, or anti-angiogenic agent, such as, for example, angiostatin, bevacizumab, sorafenib, baculostatin, canstatin, maspin, anti-VEGF
  • terapéuticaally effective means the amount of each agent administered that will achieve the goal of improvement in a disease, condition, and/or disorder severity, while avoiding or minimizing adverse side effects associated with the given therapeutic treatment.
  • pharmaceutically acceptable means that the subject item is appropriate for use in a pharmaceutical product.
  • an embodiment of this invention includes a method of treating the various conditions in a patient (including mammals) which comprises administering to said patient a composition containing an amount of an antibody of the invention that is effective in treating the target condition.
  • the antibodies of the present invention may be used in the treatment or prevention of various diseases including, but not limited to, cancer, infectious disease, and autoimmune diseases.
  • the antibodies of the present invention or compositions including the antibodies may include a cytotoxic agent (e.g., monomethylauristatin-E) that is conjugated to the antibody.
  • a cytotoxic agent e.g., monomethylauristatin-E
  • Antibodies of the present invention may be administered alone or in combination with one or more additional therapeutic agents.
  • Combination therapy includes administration of a single pharmaceutical dosage formulation which contains an antibody of the present invention and one or more additional therapeutic agents, as well as administration of the antibody of the present invention and each additional therapeutic agents in its own separate pharmaceutical dosage formulation.
  • an antibody of the present invention and a therapeutic agent may be administered to the patient together in a single oral dosage composition or each agent may be administered in separate oral dosage formulations.
  • the antibody of the present invention and one or more additional therapeutic agents may be administered at essentially the same time (e.g., concurrently) or at separately staggered times (e.g., sequentially).
  • the antibody may be tested in vivo in a mouse xenograft tumor model.
  • An example of a therapeutic model is detailed in Example 8.
  • the antibodies described herein may be provided in a pharmaceutical composition
  • a pharmaceutically acceptable carrier may be non-pyrogenic.
  • the compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water.
  • aqueous carriers may be employed including, but not limited to saline, glycine, or the like. These solutions are sterile and generally free of particulate matter. These solutions may be sterilized by conventional, well known sterilization techniques (e.g., filtration).
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, and the like.
  • concentration of the antibody of the invention in such pharmaceutical formulation may vary widely, and may be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of administration selected. If desired, more than one type of antibody may be included in a pharmaceutical composition.
  • compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.
  • these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations which may be used pharmaceutically.
  • Pharmaceutical compositions of the invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means.
  • Formulations suitable for subcutaneous, intravenous, intramuscular, and the like; suitable pharmaceutical carriers; and techniques for formulation and administration may be prepared by any of the methods well known in the art (see, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 20 th edition, 2000).
  • the present invention also provides diagnostic methods with which a particular antigen may be detected in a patient sample or biological sample.
  • diagnostic methods may be used, for example, to diagnose disorders in which a particular antigen is elevated or reduced.
  • disorders include, but are not limited to, cancer, infectious disease, and autoimmune diseases.
  • detection of an amount of the antibody-antigen complex in a sample from a patient which is greater than an amount of the complex in a normal sample identifies the patient as likely to have the disorder
  • the patient sample may be contacted with an antibody of the invention, and the patient sample may then be assayed for the presence of an antibody-antigen complex.
  • the antibody may comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • the antibody may be bound to a solid support, which may accommodate automation of the assay.
  • Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art may be used to attach the antibody to the solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached to the antibody and the solid support. Binding of antigen and the antibody may be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.
  • a therapeutically effective dose refers to the amount of an antibody that may be used to effectively treat a disease (e.g., cancer) compared with the efficacy that is evident in the absence of the therapeutically effective dose.
  • the therapeutically effective dose may be estimated initially in animal models (e.g., rats, mice, rabbits, dogs, or pigs).
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information may then be used to determine useful doses and routes for administration in humans.
  • Therapeutic efficacy and toxicity (e.g., ED 50 —the dose therapeutically effective in 50% of the population and LD 50 —the dose lethal to 50% of the population) of an antibody may be determined by standard pharmaceutical procedures in cell cultures or experimental animals.
  • the dose ratio of toxic to therapeutic effects is the therapeutic index, and it may be expressed as the ratio, LD 50 /ED 50 .
  • the data obtained from animal studies may used in formulating a range of dosage for human use.
  • the dosage contained in such compositions may be within a range of circulating concentrations that include the ED 50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • the exact dosage may be determined by the practitioner, in light of factors related to the patient who requires treatment. Dosage and administration may be adjusted to provide sufficient levels of the antibody or to maintain the desired effect. Factors that may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Effective in vivo dosages of an antibody are in the range of about 5 ⁇ g to about 500 ⁇ g/kg of patient body weight.
  • the mode of administration of antibody-containing pharmaceutical compositions of the present invention may be any suitable route which delivers the antibody to the host.
  • pharmaceutical compositions of the invention may be useful for parenteral administration (e.g., subcutaneous, intramuscular, intravenous, or intranasal administration).
  • Antibodies 3E10 and 19G9 recognize tissue factor (TF) and tumor-associated antigen RG1, respectively. These two antibodies were used to construct protease-regulated antibodies containing the protease site DDDDK (SEQ ID NO: 26) linker located between the antigen binding domains and constant region domain. Specifically, these antibodies contained V L -DDDDK-CL on the light chain and V H -DDDDK-CH1-Myc-His6 on the heavy chain, where the linker is cleavable by enterokinase, and Myc and His6 are tags for detection and purification. The DNA sequences for the two antibodies were cloned into bacterial expression vectors using standard molecular biology technologies, and the constructs were confirmed by DNA sequencing.
  • FIGS. 8 and 9 Examples of plasmid are shown in FIGS. 8 and 9 .
  • the plasmid containing either 3E10 or 19G9 was expressed and purified from bacterial strain TG1. Briefly, a single colony of bacteria strain TG1 containing the antibody expression plasmid was selected and grown overnight in 8 ml of 2 ⁇ YT medium in the presence of 34 ⁇ g/ml chloramphenicol and 1% glucose. A volume of culture (7 ml) was transferred to 250 ml fresh 2 ⁇ YT medium containing 34 ⁇ g/ml chloramphenicol and 0.1% glucose. After 3 hours of incubation, 0.5 mM IPTG was added to induce Fab expression. The culture was incubated overnight at 25° C.
  • the culture was centrifuged to pellet the bacterial cells, and the pellet was resuspended in a Bug Buster® lysis buffer (Novagen, Madison, Wis.). After centrifugation, the bacterial lysis supernatant was filtered, and the Fab fragments were affinity-purified through a Ni-NTA column (Qiagen, Valencia, Calif.) according to the manufacturer's instruction.
  • protease-regulated antibodies were also constructed using tandem linked variable regions from 3E10 and 19G9. These antibodies contained, for example, V L 3E10-DDDDK-V L 19G9-CL on the light chain and V H 3E10-DDDDK-V H 19G9-CH1-Myc-His6 on the heavy chain, where the linker is cleavable by enterokinase, and Myc and His6 are tags for detection and purification.
  • An antibody library was also constructed using the framework regions (FR), for example, FR4 of 3E10 and FR1 of 19G9 either intact or truncated.
  • FR4 of 3E10 and FR1 of 19G9 either intact or truncated.
  • the expression vector pIE_SRgamma_fa contains cDNAs encoding the constant regions of human IgG1 (fa haplotype) and kappa chains, respectively. An overlap PCR was performed to link the variable regions of anti-TF antibody 3E10 and anti-RG1 antibody 19G9. The native signal peptide of 19G9 was used for secretion of the protease-regulated antibodies.
  • Linker 1 SDDDDK (SEQ ID NO: 2)
  • Linker 2 GGGGSDDDDK (SEQ ID NO: 3)
  • Linker 3 GGGGSDDDDKGGGGS (SEQ ID NO: 4)
  • Linker 4 GGGGSGGGGSGGGGS (SEQ ID NO: 5).
  • the primers for amplification of the variable region of the light chain introduced Hind III and Bsiw I sites into the 5′ and 3′ ends of PCR fragment, respectively.
  • V L genes were cloned into the HindIII/Bsiw site of pIE_SRgamma1_fa to create pIE-3E10V L -linker-19G9V L .
  • the same strategy was used to clone in frame V H fusions of 3E10 and 19G9 (including linkers 1-4) into pIE-3E10V L -linker-19G9V L .
  • the primer pairs of the variable regions of 3E10 and 19G9 contained NotI/ApaI sites.
  • PCR products were digested with NotI/ApaI and inserted upstream of the CH region of pIE-3E1OV H -linker-19G9V H ensuring that the V H regions were in frame with the CH region in the respective pIE derivatives.
  • the fmal constructs were verified by DNA sequencing analysis.
  • Transfection and transient expression of the protease-regulated antibodies were conducted using mammalian cells. Approximately 4 ⁇ 10 8 CHO-S cells supplemented with CHO-SF medium were prepared for transfection. Transfection was carried out using LipofectamineTM 2000 (Invitrogen, Carlsbad, Calif.) and 1 mg plasmid DNA following the manufacturer's instruction. The cells were grown for three days after transfection, and the culture media was harvested and filtered for antibody isolation and purification.
  • protease-regulated antibodies examples are described in Tables 3-9.
  • Biotinylated TF (1 ⁇ g/ml) was added to streptavidin pre-coated 96-well plates (Pierce Chemical, Rockford, Ill.) and incubated for 1 hr. The plates were then washed (5 ⁇ ) with PBS containing 0.5% Tween-20. Samples and controls (serially diluted) were added to the wells and incubated for 1 hr, followed by washes (5 ⁇ ) with PBS containing 0.5% Tween-20. Horseradish peroxidase (HRP)-conjugated anti-human IgG or HRP-conjugated anti-human Fab were diluted in PBS (1:5000) and added to each well.
  • HRP horseradish peroxidase
  • the antigen binding activity of a bispecific protease-regulated antibody (illustrated in FIG. 2 ) was measured using a sandwich antigen-binding ELISA.
  • This antibody binds two antigens, RG-1 and TF, and the linker contains cleavage sites for enterokinase (“EK”).
  • HRP horseradish peroxidase
  • streptavidin 1:10000 diluted
  • Amplex Red 10 ⁇ g/ml
  • Parental antibodies 3E10, 19G9, and polyclonal human Fab were used as controls. The results are the average of duplicate wells ( FIG. 12 ).
  • the untreated bispecific protease-regulated antibody simultaneously binds to both TF and RG-1 (“Link1” and “Link2,” respectively). However, following enterokinase treatment, the binding to both antigens is greatly reduced (“Link1/EK” and “Link2/EK,” respectively).
  • protease-regulated antibodies The antigen binding activity of several examples of protease-regulated antibodies was also measured using this assay.
  • the antigen binding activity of protease-regulated antibodies 3E10-Type1-Fab and 19G9-Type1-Fab is shown in FIG. 13 .
  • the controls are designated 3E10-Reg-Fab, 19G9-Reg-Fab, and HuFab.
  • FIG. 14 The antigen binding activity of Fab-like protease-regulated antibodies is demonstrated in FIG. 14 .
  • Parental antibodies 3E10, 19G9, and polyclonal human Fab were used as controls.
  • FIG. 15 shows the antigen binding activity of Fab-like protease-regulated antibodies H2L1, H2L2, and H2L8 (Type 3) and H3L1, H3L4, and H5L4 (Type 4).
  • Protease-regulated antibodies were digested with EnterokinaseMaxTM, the catalytic subunit of enterokinase (Invitrogen, Carlsbad, Calif.). The concentration of antibodies was adjusted to 1-5 ⁇ g/ml. A volume of antibody (100 ⁇ l) was mixed with 20 ⁇ l 10 ⁇ EnterokinaseMaxTM buffer and 75 ⁇ l sterile water in a tube. EnterokinaseMaxTM (5 ⁇ l) was added to each sample and the samples were incubated at 37° C. for 16 hr. For the control group, a volume of water (5 ⁇ l) was used.
  • HRP horseradish peroxidase
  • the membrane was then washed in PBS containing 0.5% Tween-20, and incubated with SuperSignal West Femto (Pierce Chemical, Rockford, Ill.), and expose to X-ray film for development. Results are shown in FIGS. 16-18 .
  • MaTu cells are maintained as adherent cultures in RPMI supplemented with 10% FBS.
  • Ncr nude mice (8-12 weeks of age) are inoculated subcutaneously in the right flank with 5 ⁇ 10 6 cells in 0.1 mL of 80% matrigel/20% HESS. When tumors reach an average size of ⁇ 180 mg (6 days), treatment is initiated.
  • Antibodies are administered i.v. once every four days (Q4D ⁇ 3) at a dose of 10 mg/kg.
  • Control mice are treated with PBS or an unconjugated monoclonal antibody. Daily examinations into the health status of each animal are conducted. Each experimental group consists of 10 mice and the dosing volume was 0.1 mL/10 g body weight.
  • TGI Tumor growth inhibition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)

Abstract

This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.

Description

  • This application claims benefit to U.S. Provisional Application Ser. No. 60/955,912, filed Aug. 15, 2007, and U.S. Provisional Application Ser. No. 60/955,913, filed Aug. 15, 2007, the contents of which are incorporated herein by reference in their entirety.
    • FIELD OF THE INVENTION
  • This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.
    • BACKGROUND OF THE INVENTION
  • An antibody may be directed against one or more different antigens or one or more different epitopes on the same antigen. For example, a bispecific antibody is directed against two different antigens or two different epitopes on the same antigen. As bispecific antibodies can simultaneously bind to two distinct targets, these antibodies have great potential for antibody-based diagnosis and for the treatment of various diseases and disorders such as cancer, infectious diseases, autoimmune diseases, and blood diseases. For example, bispecific antibodies can selectively stimulate and expand T lymphocytes (Wong, et al., J. Immunol 139:1369-1374, 1987; Wong, et al., Clin. Immunol. Immunopathol. 58:236-250, 1991), direct immune cells or toxic agents to kill tumor cells (Lum, et al., Exp. Hematol. 34:1-6,2006; Wolf, et al., Drug Discov. Today 10:1237-1244, 2005; Cao, et al., Adv. Drug Deliv. Rev. 55:171-197, 2003; Talac, et al., J. Biol. Regul. Homeost. Agents 14:175-181, 2000), and simultaneously block two receptors (Lu, et al., J. Biol. Chem. 279:2856-2565, 2004). In addition, a bispecific antibody may be used as a substitute for Factor VIII to enhance enzymatic reaction (US Patent Application No. 2007/0041978) or to direct stem cells to the site of injury in patients with myocardial infarction (Lum, et al., Blood Cells Mol. Dis. 32:82-87, 2004).
  • Bispecific antibodies targeting tumor-associated antigens and toxic agents may be used in cancer therapy. For example, using this technology, one arm of the bispecific antibody may be directed to a tumor-associated antigen such as Her2, EGF receptor, CD20, CD22, CD30, CD33, CD52, and CA-125, and the other arm of the bispecific antibody may target a toxin, drug, or cytokine. That is, bispecific antibodies may selectively direct toxic agents to tumor cells enhancing the efficacy of therapeutic antibodies and decreasing systemic toxicity. Examples of toxin/drug include calicheamicin, doxorubicin, epirubicin, methotrexate, ricin A, saporin, gelonin, and vinca alkaloids, and cytokine examples include tumor necrosis factor alpha (TNF-alpha) and IL-2.
  • Specific cleavage by proteases of defined sites in biologically important effector proteins is a well known method for the natural control of cellular and extracellular physiological processes. Examples include protease activation and inhibition of the coagulation cascade (Butenas, et al., Biochemistry 67:3-12, 2002; Esmon, Chest, 124:26S-32S, 2003), protease activation of protease-activatable receptors (Coughlin, Arterioscler. Thromb. Vasc. Biol. 18:514-518, 1998), protease release of membrane associated cytokines (Amour, et al., FEBS Lett. 435:39-44, 1998), protease processing of prohormones in secretory vesicles (Moore, et al., Arch. Physiol. Biochem. 110:16-25, 2002), and protease processing of proproteins during secretion (Scamuffa, et al., FASEB J. 20:1954-1963, 2006). Proteases are often expressed or located in a tissue-specific or tumor-specific manner and examples include the membrane serine protease corin in heart tissue (Yan, et al., Proc. Natl. Acad. Sci. USA 97:8525-8529, 2000), the kallikrein serine protease prostate-specific antigen (PSA) in prostate tissue, prostate cancer, and seminal fluid (Veveris-Lowe, et al., Semin. Thromb. Hemost. 33:87-99, 2007), the membrane serine protease hepsin in liver tissue and tumors (Xuan, et al., Cancer Res. 66:3611-3619, 2006), coagulation protease factor X expressed in the liver and secreted into blood (Miao, et al., J. Biol. Chem. 267:7395-7401, 1992), and digestive proteases expressed in the pancreas and released to the duodenum (Belorgey, et al., Biochem. J. 313:555-560, 1996). Specific cleavage of amino acid sequences by human proteases include thrombin (Chang, Eur. J. Biochem. 151:217-224,1985), factor Xa (Nagai, et al., Methods Enzymol. 153:461-481, 1987), furin (Brennan, et al., FEBS Lett. 347:80-84, 1994), subtilisin-like prohormone convertases (Lipkind, et al., J. Biol. Chem. 270:13277-13284, 1995), and the matrix metalloproteinases (Minod, et al., J. Biol. Chem. 281:38302-38313, 2006). Genes encoding specific proteases may be up-regulated in tumor tissue and Table 2 indicates proteases that are associated with cancer tissue.
  • Protease cleavage is widely used in in vitro studies to specifically remove protein or peptide tags from recombinant proteins or to process hybrid recombinant proteins. For example, human rhinovirus 3C protease, thrombin, or factor Xa have been used to remove glutathione S-transferase (GST) tags (Dian, et al., Life Sciences News—Amersham Biosciences 10:1-5, 2002) and factor Xa has been use to process hybrid proteins (Nagai, et al., 1987). Proteases are often targets for drugs as a means to regulate biological processes; and examples include factor Xa (Phillips, et al., J. Med. Chem. 41:3557-3562,1998), thrombin (Riester, et al., Proc. Natl. Acad. Sci. USA 102:8597-8602, 2005), urokinase (Killeen, et al., Br. J. Cancer 96:262-268, 2007), and factor Vila (Kohrt, et al., Bioorg. Med. Chem. Lett. 15:4752-4756, 2005). Finally, proteins developed as biological drugs may be modified to prevent cleavage by proteases and to improve their stability in vitro or in vivo (Light, et al., Eur. J. Biochem. 262:522-533, 1999; Saenko, et al., Haemophilia 12:42-51, 2006).
  • Specific protease cleavage sites have been incorporated into linkers that link a toxin molecule to a targeting antibody in order to allow protease specific release of the toxin by intracellular proteases (Trail, et al., Cancer Immunol. Immunother. 52:328-337, 2003). Furthermore, targeting antibodies have been created in many formats. For example, bispecific antibodies have been developed to allow binding to two different antigens or two different epitopes of an antigen by a single antibody molecule (Segal, et al., Curr. Opin. Immunol. 11:558-562, 1999; Tomlinson, et al., Methods Enzymol. 326:461-479, 2000; Wu, et al., Nat Biotechnol. 25:1290-1297, 2007). Other bispecific molecules have been generated with the ability to block two receptors (Lu, et al., J. Biol. Chem. 279:2856-2865, 2004) and to recruit immune cells to attack cancer cells and tumor tissue (Loffler, et al., Leukemia 17:900-909, 2003; Lum, et al., Exp. Hematol. 34:1-6, 2006).
  • The present invention relates to a novel antibody format, for example, monospecifc and multispecific antibodies. The antibodies of the present invention may be constructed by tandem linking of two different heavy chain (H) variable region domains (VH) and two different light chain (L) variable region domains (VL). The heavy chain and light chain may form a Fab-like or IgG-like molecule through the disulfide bond between constant (C) regions. Multispecific antibodies may be generated by linking more than two antibody variable domains.
  • The antibodies of the present invention may be modified by protease cleavage. These protease-regulated antibodies may be, for example, monospecific antibodies, bispecific antibodies, or antibodies with sequential binding-activity upon protease digestion in either, for example, Fab-like or IgG-like format. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may be utilized for the diagnosis and treatment of various diseases, and provide an additional level of control for biological drugs for therapeutic or diagnostic applications.
    • DESCRIPTION OF THE FIGURES
  • FIG. 1. Schematic drawing of a monospecific protease-regulated antibody with a linker which contains a protease site between variable domain and Fc domain (“Type 1”).
  • FIG. 2. Schematic drawing of a bispecific protease-regulated antibody with a linker which contains a protease cleavage sequence that allows removal of one antigen-binding site (“Type 2”).
  • FIG. 3. Schematic drawing of another bispecific protease-regulated antibody with a linker which contains a protease cleavage sequence that allows removal of one antigen-binding site (“Type 2”).
  • FIG. 4. Schematic drawing of the application of a bispecific protease-regulated antibody that simultaneously binds two different antigens.
  • FIG. 5. Schematic drawing of a protease-regulated antibody that cannot bind to two different antigens simultaneously (“Type 3”).
  • FIG. 6. Schematic drawing of the application of a protease-regulated antibody that cannot bind to two different antigens simultaneously.
  • FIG. 7. Schematic drawing of a monospecific protease-regulated antibody ‘prodrug’ that can only bind antigen following protease activation to remove inactive blocking antibody domains (“Type 4”).
  • FIG. 8. Map of an expression vector for an IgG-like bispecific antibody. SignalP: signal peptide; VLam3E10: variable region of 3E10 lambda chain; Vk19G9: variable region of 19G9 kappa chain; C kappa: constant region of kappa chain; DHFR: dihydrofolate reductase; VH: variable region of heavy chain; Neo: neomycin resistant gene; 3E10VH: variable region of 3E10 heavy chain; 19G9VH: variable region of 19G9 heavy chain; CH: constant region of heavy chain; Amp: ampicillin resistant gene.
  • FIG. 9. Map of expression vector of Fab-like bispecific antibody. LacZ, lac Z promoter; ompA and pho A, signal peptide; VL-linkl-VK, variable region of light chain of bispecific antibody against tissue factor and RG1; CL-kappa, constant region of kappa chain; VHs with linker, variable region of heavy chain of bispecific antibody against tissue factor and RG1; CH1, the first constant region of IgG heavy chain; cat, chloramphenicol resistant gene.
  • FIG. 10. TF-binding ELISA. Four bispecific antibodies and parental antibodies were analyzed for binding to TF. Antibodies were detected with HRP-conjugated anti-human IgG was used for detection. Curve fitting of the data was performed using a 4-parameter equation with the Solver function in Microsoft Excel. Positive control anti-TF IgG 3E10x: IC50=2.0 nM (filled diamond, solid line); Linker 1 (SEQ ID NO: 1) IgG-like bispecific antibody: IC50=0.78 nM (filled triangle, large dashed line); Linker 2 (SEQ ID NO: 2) IgG-like bispecific antibody: IC50=0.93 nM (open triangle, small dashed line); Linker 3 (SEQ ID NO: 3) IgG-like bispecific antibody: IC50=1.06 nM (filled square, alternating small and large dashed line); Linker 4 (SEQ ID NO: 4) IgG-like bispecific antibody: IC50=1.01 nM (open square, two large and one small dashed line); and negative control anti-RG1 IgG 19G9: no binding (open diamond, solid line).
  • FIG. 11. RG1-binding ELISA. A bispecific antibody containing Linker 1, anti-RGI antibody 19G9, and polyclonal nonimmune control human IgG kappa were analyzed for binding to RG-1. Curve fitting of the data was performed using a 4-parameter equation with the Solver function in Microsoft Excel. Positive control anti-RG1 IgG 19G9: IC50=1.4 nM (filled diamond, solid line); Linker 1 (SEQ ID NO: 1) IgG-like bispecific antibody: IC50=1.1 nM (filled triangle, large dashed line); and negative control nonimmune polyclonal human IgG kappa: no binding (open triangle, small dashed line).
  • FIG. 12. Measurement of the antigen-binding activity of a bispecific protease-regulated antibody using a sandwich antigen-binding ELISA. The linker of this antibody contained cleavage sites for enterokinase.
  • FIG. 13. Measurement of the antigen-binding activity of protease-regulated antibodies 3E10-Typel-Fab and 19G9-Typel-Fab. The controls are designated 3E10-Reg-Fab, 19G9-Reg-Fab, and HuFab.
  • FIG. 14. Measurement of the antigen-binding activity of Fab-like protease-regulated antibodies H1L1, H1L4, H1L7, H14L7, and H5L5 (Type 2) in the absence and presence of enterokinase. Parental antibodies 3E10 and 19G9, and polyclonal human Fab were used as control.
  • FIG. 15. Measurement of the antigen-binding activity of Fab-like protease-regulated antibodies H2L1, H2L2, and H2L8 (Type 3) and H3L1, H3L4, and H5L4 (Type 4) in the absence and presence of enterokinase. Parental antibodies 3E10 and 19G9, and polyclonal human Fab were used as control.
  • FIG. 16. Western blots of protease-regulated antibody 3E10-Type1-Fab detected with anti-Myc antibody (A) or anti-kappa chain antibody (B). Lane 1 and 2: 3E10-Typel-Fab without or with enterokinase digestion, respectively. Lane 3 and 4: 3E10-Reg-Fab without or with enterokinase digestion, respectively.
  • FIG. 17. Western blots of Fab-like protease-regulated antibodies H1L1, H1L7, and H5L5 (Type 2) in the absence and presence of enterokinase. Antibodies were detected with anti-IgG(H+L) antibody. Lane 1 and 2: H1L1 without or with enterokinase digestion, respectively. Lane 3 and 4: H1L7 without or with enterokinase digestion, respectively. Lane 5 and 6: H5L5 without or with enterokinase digestion, respectively. Lane 7: 3E10-Reg-Fab.
  • FIG. 18. Western blots of Fab-like protease-regulated antibodies H2L2 and H2L8 (Type 3) and H3L4 (Type 4) in the absence and presence of enterokinase. Antibodies were detected with anti-Myc antibody. Lane 1 and 2: H2L2 without or with enterokinase digestion, respectively. Lane 3 and 4: H2L8 without or with enterokinase digestion, respectively. Lane 5 and 6: H3L4 without or with enterokinase digestion, respectively.
    •  DESCRIPTION OF THE INVENTION
  • It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
  • It must be noted that as used herein and in the appended claims, the singular forms “a,” “and,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “an antibody” is a reference to one or more antibodies and includes equivalents thereof known to those skilled in the art, and so forth.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.
  • All publications and patents mentioned herein are hereby incorporated herein by reference for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications which might be used in connection with the presently described invention. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.
  • For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below.
  • “Antibody” as used herein includes intact immunoglobulin molecules (e.g., IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA), as well as fragments thereof, such as Fab, F(ab′)2, scFv, Fv, and diabody which are capable of specific binding to an epitope of a protein. The term antibody also extends to other protein scaffolds that are able to orient antibody complementarity-determining region (CDR) inserts into the same active binding conformation as that found in natural antibodies such that the binding to the target antigen observed with these chimeric proteins is maintained relative to the binding activity of the natural antibody from which the CDRs were derived.
  • “Antibody fragments” comprise a portion of a full length antibody, generally the antigen binding or variable domain thereof. Examples of antibody fragments include Fab, Fab′, F(ab′)2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; monospecific antibodies; bispecific antibodies; and multispecific antibodies formed from antibody fragments.
  • The term “autoimmune diseases” includes, but is not limited to, multiple sclerosis, rheumatoid arthritis, lupus, type I diabetes mellitus, Crohn's disease, autoimmune hemolytic anemia, autoimmune hepatitis, glomerulonephritis, inflammatory bowel disease, myocarditis, psoriasis, thyroiditis, ulcerative colitis, and Graves'disease.
  • The terms “biological sample” or “patient sample” as used herein, refers to a sample obtained from an organism or from components (e.g., cells) of an organism. The sample may be of any biological tissue or fluid. The sample may be a “clinical sample” which is a sample derived from a patient. Such samples include, but are not limited to, sputum, blood, serum, plasma, blood cells (e.g., white cells), tissue samples, biopsy samples, urine, peritoneal fluid, and pleural fluid, saliva, semen, breast exudate, cerebrospinal fluid, tears, mucous, lymph, cytosols, ascites, amniotic fluid, bladder washes, and bronchioalveolar lavages or cells therefrom, among other body fluid samples. The patient samples may be fresh or frozen, and may be treated with heparin, citrate, or EDTA. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes.
  • The term “cancer” includes, but is not limited to, solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, and their distant metastases. The term also includes lymphomas, sarcomas, and leukemias.
  • The term “ conjugate” refers to an antibody chemically linked to a chemical moiety, such as a therapeutic or cytotoxic agent.
  • The term “infectious diseases” includes, but is not limited to, HIV/AIDS, lower respiratory infections, diarrheal diseases, tuberculosis, malaria, measles, pertussis, tetanus, meningitis, syphilis, hepatitis B and tropical diseases.
  • The term “linker” refers to a peptide (or polypeptide) comprising two or more amino acid residues joined by peptide bonds and used to link one or more antibody domains. The linker may contain one or more protease cleavage sites.
  • The term “protease” refers to any enzyme, including the endopeptidases and exopeptidases, which catalyze the hydrolytic breakdown of proteins into peptides or amino acids.
  • The present invention is directed to the design and production of monospecific, bispecific antibodies, and multispecific antibodies. For example, the bispecific antibodies and multispecific antibodies may comprise tandem linked VHa-VHb-VHc . . . CH in one polypeptide and VLa-VLb-VLc . . . CL in another polypeptide. Alternately, the VH and VL domains may be exchanged from one polypeptide to another to create polypeptides such as VHa-VLb-VHc . . . CH and VLa-VHb-VLc . . . CL. The two polypeptides may form □immers in the Fab format or the half IgG-like format, or two of each polypeptide may form a four polypeptide-containing homodimer of the IgG-like format. These bispecific or multispecific antibodies or antibody fragments thereof may simultaneously bind different antigens or different epitopes of the same antigen.
  • As an example, a recombinant IgG-like bispecific antibody may be constructed by the tandem linking of two different VH domains of a heavy chain and two different VL domains of a light chain. The construct is exemplified as follows:

  • heavy chain=NH2-VH1-VH2-CH1-CH2-CH3-COOH

  • light chain=NH2-VL1-VL2-CL.
  • Another bispecific antibody may comprise the following:

  • heavy chain=NH2-VL1-VH2-CH1-CH2-CH3-COOH

  • light chain=NH2-VH1-VL2-CL-COOH.
  • The present invention also relates to protease-regulated antibodies. Protease-regulated antibodies may be, for example, monospecific antibodies, bispecific antibodies, multispecific antibodies, or antibodies with sequential binding-activity upon protease digestion in either, for example, Fab-like or IgG-like format. Protease control or regulation may be provided by a selective protease site located in, for example, a linker. These protease-regulated antibodies may be utilized for the diagnosis and treatment of various diseases including but not limited to cancer, infectious disease, and autoimmune diseases, and provide an additional level of control for biological drugs for therapeutic or diagnostic applications.
  • Protease-regulated antibodies may comprise a heavy chain (H) variable domain (VH)-linker-heavy chain constant domain (CH) in one polypeptide and a light chain (L) variable domain (VL)-linker-light chain constant domain (CL) in another polypeptide. Bispecific protease-regulated antibodies may comprise, for example, VH1-linker-VH2-CH in one polypeptide and VL1-linker-VL2-CL in another polypeptide, both regulated by proteolytic cleavage of the linker. Alternately, the VH and VL domains in the bispecific protease-regulated antibodies may be exchanged from one polypeptide to another polypeptide to create polypeptides such as, for example, VH1-linker-VL2-CH and VL1-linker-VH2-CL. The two polypeptides may form □immers, for example, in a Fab-like format, a half-IgG-like format, or an IgG-like format (e.g., two of each polypeptide forming a four polypeptide-containing homodimer). The bispecific and sequential protease-regulated antibodies or antibody fragments may (1) simultaneously bind two different antigens or different epitopes of the same antigen, (2) sequentially bind two different antigens or different epitopes on the same antigen in a manner that may be dependent on the length, adjacent sequence, and design of the linker, or (3) a monospecific protease-activated binder which is in latent or prodrug form prior to protease digestion and which is switched on by protease cleavage. Libraries of bispecific protease-regulated antibodies in the Fab-like format can be readily created, expressed in bacteria, and screened for specific functionalities, including susceptibility of the linker to cleavage by a specific protease and optimization of this cleavage step.
  • Several types of protease-regulated antibodies are described herein whereby antibody formats are designed with selectivity due to specific protease-dependent binding or protease-specific functionality. In particular, these protease-regulated antibodies may be described by deletions and/or additions of antibody framework, location of the linker, and its properties including length and solvent accessibility. Furthermore, the linker may contain a cleavage site specific for a protease found in a target cell or tissue. One example of a protease-regulated antibody may contain a protease site in a linker located between the variable domain and the constant region domain and this antibody may bind only one antigen as illustrated in FIG. 1 (“Type 1”).
  • Another example of a protease-regulated antibody may simultaneously bind two different antigens or two different epitopes as shown in FIGS. 2 and 3 (“Type 2”) in the absence of a protease. The first VH/VL domains of this antibody bind to an antigen without blocking the second VH/NL domains from binding to a second antigen. This antibody can bind to antigens without steric blocking of the CDR regions of the second variable domains. The simultaneous binding of this protease-regulated antibody to both antigens is prevented by proteolytic cleavage. That is, when the linker is cleaved by a protease, the antibody can only bind to the second antigen or separately bind two antigens. Simultaneous antigen binding is important for antibody function, for example, in cross-linking receptors, which may be prevented by proteolytic cleavage. Thus, an additional degree of specificity is added by including a protease site in the linker.
  • This bispecific protease-regulated antibody is more selective than a monospecific antibody because this antibody will specifically target cells or tissues expressing both antigens. The additional degree of specificity is provided by the specific protease site in the linker. In FIG. 4, Cell A and Cell B express both Antigen 1 and Antigen 2, however only Cell B expresses the selective protease. The bispecific protease-regulated antibody with the uncleavable linker (i.e., this linker does not contain the protease cleavage site) will bind to Cell A with greater avidity because the bispecific antibody is able to bind to both antigens. In contrast, the bispecific protease-regulated antibody will bind to Cell B with lower avidity because the Antigen 1 binding domain is removed by proteolytic cleavage of the linker by the selective protease expressed by Cell B (alternately, the selective protease may be expressed by adjacent cells localized in the same tissue as Cell B).
  • In contrast, FIG. 5 illustrates a protease-regulated antibody that may sequentially bind to each antigen in a protease-dependent manner. That is, prior to protease cleavage of the linker, the protease-regulated antibody binds to a first antigen and following protease cleavage, the antibody binds to a second antigen (“Type 3”). The VH/VL domains of the N-terminal antibody bind to an antigen, but block the CDR regions of the downstream VH/VL domains from binding to a second antigen. Protease cleavage of the linker allows removal of the N-terminal antibody, and removing the N-terminal antibody domains then permits binding to a second antigen. This allows for greater cell and/or tissue selectivity by requiring sequential binding.
  • In FIG. 6, Cell A and Cell B express both Antigen 1 and Antigen 2, but only Cell B expresses the selective protease. In addition, Antigen 2 is a cell surface receptor that internalizes into the cell and allows internalization of antibodies that bind to it. The protease-regulated antibody will bind to Antigen 1 expressed by Cell A and Cell B. However, only Cell B expresses the selective protease (or possibly cells adjacent to Cell B in the same tissue). The protease-regulated antibody will be activated by proteolytic cleavage and internalized via Antigen 2 expressed on Cell B. Thus, this protease-regulated antibody will be specifically internalized by cells expressing Antigen 1, Antigen 2, and the selective protease.
  • In an additional example, a protease-regulated antibody may not bind to an antigen before protease digestion, but may bind to antigen following protease digestion (“Type 4”). An example of this antibody is illustrated in FIG. 7. This monospecific protease-regulated antibody also contains a protease cleavage linker that allows removal of the N-terminal non-functional antibody which then leads to binding to an antigen by the functional antibody domains that are thus exposed. Type 4 protease-regulated antibodies may be created by three approaches. In the first approach the protease cleavable linker sequence is modified so that it prevents the N-terminal VH and VL domains of a Type HI antibody (V H1 and VL1) from binding to the first antigen. Examples of these linkers are shown in the sequences in Table 8. In the second approach, the linkers utilized in Type III antibodies shown in Tables 6 and 7 are now combined with heterodimeric N-terminal VH and VL domains that have been mutated to destroy their antigen binding function. Examples of this approach are shown in the sequences in Table 9 in which the CDR3 of V H1 and CDR3 of V L1 are replaced by a poly-alanine sequence of a similar length as the respective CDR. In the third approach, the linkers utilized in Type III antibodies shown in Tables 6 and 7 are combined with homodimeric N-terminal domains derived from the constant regions of antibodies. For example, the complete V H1 and V L1 domains of a Type III antibody are both replaced by the same constant domain that is capable of heterodimerization, for example, the CH3 domain of IgG or the CH4 domain of IgE.
  • These protease-regulated antibodies may be modified by protease cleavage of the linker as described below. For example, the protease-regulated antibody illustrated in FIG. 1 (Type 1) contains a protease site in the linker between the antigen binding domains and the Fc domain. This antibody will specifically target cells or tissues that present the antigen. When the linker is cleaved by the protease, the resultant protease-regulated antibody releases the functional Fc portion. In tissues where the protease is present, this antibody will release the Fc portion which is essential to antigen crosslinking, and induce an immune response such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). To illustrate, hepsin, a serine protease, is expressed in both tumor tissue and normal liver tissue. In a cancer patient treated with a protease-regulated antibody against hepsin, the antibody would attack the tumor cells via the Fc portion-induced ADCC and CDC. However, in the liver, the protease-regulated antibody would initially bind to hepsin, but the Fc portion would be cleaved by a liver-specific protease prior to initiation of ADCC or CDC preventing liver toxicity.
  • The peptide (or polypeptide) linker of the protease-regulated antibody may comprise two or more amino acid residues and may contain one or more protease cleavage sites. The linkers may alter antibody conformation, stability, and antigen-binding activities. The length of linkers may range, for example, from 0 to about 100 amino acid residues. The following are examples of linkers:
  •  (SEQ ID NO: 1)
    Linker 1: SDDDDK
     (SEQ ID NO: 2)
    Linker 2: GGGGSDDDDK
     (SEQ ID NO: 3)
    Linker 3: GGGGSDDDDKGGGGS
     (SEQ ID NO: 4)
    Linker 4: GGGGSGGGGSGGGGS
     (SEQ ID NO: 5)
    Linker 5: IHPVLSGLSRIVNGEDAVPG
     (SEQ ID NO: 6)
    Linker 6: VAAPFDDDDKIVGGYICEEN
     (SEQ ID NO: 7)
    Linker 7: ELLESYIDGRIVEGSDAEIG
     (SEQ ID NO: 8)
    Linker 8: STQSFNDFTRVVGGEDAKPG
     (SEQ ID NO: 9)
    Linker 9: PERGDNNLTRIVGGQECKDG
     (SEQ ID NO: 10)
    Linker 10: EDQEDQVDPRLIDGKMTRRG
     (SEQ ID NO: 11)
    Linker 11: KRNASKPQGRIVGGKVCPKG
     (SEQ ID NO: 12)
    Linker 12: SVCTTKTSTRIVGGTNSSWG
     (SEQ ID NO: 13)
    Linker 13: SRIVG
     (SEQ ID NO: 14)
    Linker 14: GSLVSGSCSQIINGEDCSPH
     (SEQ ID NO: 15)
    Linker 15: SRIIN
     (SEQ ID NO: 16)
    Linker 16: NKLVH 
     (SEQ ID NO: 17)
    Linker 17: DKIID
     (SEQ ID NO: 18)
    Linker 18: FNVLG
     (SEQ ID NO: 19)
    Linker 19: TRAIG
     (SEQ ID NO: 20)
    Linker 20: TRLDP
     (SEQ ID NO: 21)
    Linker 21: TRIIK
     (SEQ ID NO: 22)
    Linker 22: SGSNQ 
     (SEQ ID NO: 23)
    Linker 23: SKVLN
     (SEQ ID NO: 24)
    Linker 24: NKIIG
     (SEQ ID NO: 25)
    Linker 25: DKLLE 
  • Table 1 illustrates the excision site of several proteases.
  • TABLE 1 
    Cleavage Enzyme/
    Excision site ↓ Self-Cleavage
    Asp-Asp-Asp-Asp-Lys↓ Enterokinase
    (DDDDK) (SEQ ID NO: 26)
    Ile-Glu/Asp-Gly-Arg↓ Factor Xa 
     (IE/DGR) (SEQ ID NO: 27) protease
    Leu-Val-Pro-Arg↓Gly-Ser Thrombin
    (LVPR|GS) (SEQ ID NO: 28)
    Glu-Asn-Leu-Tyr-Phe-Gln↓Gly TEV protease
    (ENLYFQ|G) (SEQ ID NO: 29)
    Leu-Glu-Val-Leu-Phe-Gln↓Gly-Pro Human rhinovirus
    (LEVLFQ|GP) (SEQ ID NO: 30) 3C protease
    Ser-Ser-Val-Phe-Ala-Gln↓Ser- PCSK9 (NARC-1)
    Ile-Pro
    (SSVFAQ|SIP) (SEQ ID NO: 31)
    Lys-Gln-Leu-Arg↓Val-Val-Asn-Gly Hepsin
    (KQLR|VVNG) (SEQ ID NO: 32)
    Specific intein-encoded  Intein 1 & 
    sequences intein 2
    Signal sequences Signal peptidases
  • The cleavage sites of additional proteases that may be incorporated in a linker are described in Table 2.
  • TABLE 2
    TUMOR ASSOCIATED PROTEASES (Extracellular Or Intracellular)
    ADAM metallopeptidase domain 9 (meltrin gamma)
    ADAM metallopeptidase domain 10
    ADAM metallopeptidase domain 17 (TNFalpha, converting enzyme)
    ADAM metallopeptidase domain 28
    ADAM-like, decysin 1
    ADAM metallopeptidase, thrombospondin type 1 motif 1
    ADAM metallopeptidase, thrombospondin type 1 motif 5, aggrecanase-2
    ADAMTS-like 3
    ADAMTS-like 4
    Beta-site APP-cleaving enzyme 1
    Bleomycin hydrolase
    Bone morphogenetic protein 1
    Complement component 1, r subcomponent
    Complement component 1, s subcomponent
    Calpain 2, (m/II) large subunit
    Caspase 1, apoptosis-related cysteine peptidase (Th-1β convertase)
    Caspase 2, apoptosis-related cysteine peptidase
    Caspase 3, apoptosis-related cysteine peptidase
    Caspase 4, apoptosis-related cysteine peptidase
    Caspase 6, apoptosis-related cysteine peptidase
    Caspase 7, apoptosis-related cysteine peptidase
    Caspase 9, apoptosis-related cysteine peptidase
    Complement factor D (adipsin)
    CASP8 and FADD-like apoptosis regulator
    Cathepsin B
    Cathepsin F
    Cathepsin H
    Cathepsin K
    Cathepsin L
    Cathepsin L2
    Cathepsin O
    Cathepsin S
    Cylindromatosis (turban tumor syndrome)
    Extra spindle pole bodies homolog 1 (S. Cerevisiae)
    Granzyme A (granzyme 1, CTL-associated serine esterase 3)
    Histocompatibility (minor) 13
    Hepsin (transmembrane protease, serine 1)
    HtrA serine peptidase 1
    Kallikrein-related peptidase 11
    Legumain
    Lon peptidase 1, mitochondrial
    Mucosa associated lymphoid tissue lymphoma translocation gene 1
    Membrane-bound transcription factor peptidase, site 1
    Matrix metallopeptidase 1 (interstitial collagenase)
    Matrix metallopeptidase 12 (macrophage elastase)
    Matrix metallopeptidase 14 (membrane-inserted)
    Matrix metallopeptidase 9 (gelatinase B, 92 kDa type IV collagenase)
    N-acetylated alpha-linked acidic dipeptidase-like 1
    Napsin A aspartic peptidase
    Pregnancy-associated plasma protein A, pappalysin 1
    Proprotein convertase subtilisin/kexin type 5
    Plasminogen activator, tissue
    Plasminogen activator, urokinase
    Peptidase (mitochondrial processing) beta
    Protease, serine, 3 (mesotrypsin)
    Protease, serine, 8 (prostasin)
    Proteasome (prosome, macropain) subunit, alpha type, 1
    Proteasome (prosome, macropain) subunit, alpha type, 6
    Proteasome (prosome, macropain) subunit, beta type, 4
    Proteasome (prosome, macropain) subunit, beta type, 9
    Proteasome (prosome, macropain) subunit, beta type, 10
    SUMO1/sentrin specific peptidase 1
    Suppression of tumorigenicity 14 (colon carcinoma)
    Tubulointerstitial nephritis antigen
    Torsin family 1, member A (torsin A)
    Tripeptidyl peptidase I
    Tripeptidyl peptidase II
    Tryptase alpha/beta 1
    Tryptase alpha/beta 1
    Ubiquitin specific peptidase 4 (proto-oncogene)
    Ubiquitin specific peptidase 10
    Ubiquitin specific peptidase 11
    Ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase)
    Ubiquitin specific peptidase 15
    Ubiquitin specific peptidase 16
    Ubiquitin specific peptidase 18
    Ubiquitin specific peptidase 25
    YME1-like 1 (S. cerevisiae)
    Zinc metallopeptidase (STE24 homolog, yeast)
  • The protease-regulated antibodies of the present invention may bind one or more antigens. These antigens may be selected from the group consisting of cytokines, cell surface receptors, enzymes, and receptors. These antigens include, but are not limited to, CD3, CD4, CD8, CD20, CD25, CD28, CD33, CD52, IL-2, IL-7, IL-8, TNF-alpha, TGF-beta INF-beta, INF-gamma, GMCSF, GCSF, VEGF, C5, EpCAM, EGF receptor, CD2 receptor, IL 2 receptor, IgE receptor, intergrin, and MHC class II.
  • The antibodies of the present invention may be utilized for the diagnosis and therapy of various diseases. For example, antibodies directed against human immunological cells and tumor-associated antigen may be used for cancer therapy. These antibodies may also be directed against tumor-associated antigen and toxic agents or enzymes for use as a cancer therapeutic. The antibodies of the present invention may also be utilized for the treatment of hemophilia and thrombosis as well as stem cell transplantation. These antibodies may be used for the selective stimulation and expansion of lymphocyte subset. In addition, these antibodies may used for the detection of disease-related antigens.
  • For cancer immunotherapy, bispecific antibodies may be used to recruit the immune system to attach tumor cells. Targets on immunological cells include, but are not limited to, CD3, CD8, and Fc receptor. Tumor-associated antigens include, but are not limited to, Her2, EGF receptor, CD20, CA-125, and carcinoembryonic antigen (CEA). For example, a bispecific antibody against CD8 and Her2 can direct CD8-expressing cytotoxic lymphocytes to attack Her2 expressing breast cancer cells.
  • The antibodies or antibody fragments of the invention, or compositions including the antibodies or fragments, can include a cytoxic agent that is conjugated to the antibody or fragment. In one aspect, the cytotoxic agent is monomethylauristatin-E (MMAE), however, other cytoxic agents are also provided, which can include, for example, functional analogs of MMAE (e.g. monomethylauristatin-F), and other cytotoxic agents, e.g., aplidin, azaribine, anastrozole, azacytidine, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, 10-hydroxycamptothecin, carmustine, celebrex, chlorambucil, cisplatin, irinotecan (CPT-I 1), SN-38, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, ethinyl estradiol, estramustine, etoposide, etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3′,5′-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, fluorouracil, fluoxymesterone, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, leucovorin, lomustine, mechlorethamine, medroprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, phenyl butyrate, prednisone, procarbazine, paclitaxel, pentostatin, PSI-341, semustine streptozocin, tamoxifen, taxanes, taxol, testosterone propionate, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, velcade, vinblastine, vinorelbine, vincristine, ricin, abrin, ribomiclease, onconase, rapLRl, DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin, or combinations thereof. Any of the cytoxic agents can also include functional analogs thereof.
    • Antibody Technology
  • A number of technologies are available to produce antibodies. For example, phage-antibody technology may be used to generate antibodies (Knappik, et al., J. Mol. Biol. 296:57-86, 2000). Another approach for obtaining antibodies is to screen a DNA library from B cells as described by Dower, et al., (WO 91/17271) and McCafferty, et al., (WO 92/01047). In these methods, libraries of phage are produced in which members display different antibodies on their outer surfaces. Antibodies are usually displayed as Fv or Fab fragments. Phage displaying antibodies are selected by affinity enrichment for binding to a selected protein. Antibodies may also be produced using trioma methodology (Oestberg, et al., Hybridoma 2:361-367, 1983; U.S. Pat. No. 4,634,664; U.S. Pat. No. 4,634,666).
  • Antibodies may also be purified from any cell that expresses the antibodies, including host cells that have been transfected with antibody-encoding expression constructs. The host cells may be cultured under conditions whereby the antibodies are expressed. Purified antibody may be separated from other cellular components that may associate with the antibody in the cell, such as certain proteins, carbohydrates, or lipids using methods well known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis. Purity of the preparations may be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis. A preparation of purified antibodies may contain more than one type of antibody.
  • Alternatively, antibodies may be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (see, e.g., Merrifield, J. Am. Chem. Soc. 85:2149-2154, 1963; Roberge, et al., Science 269:202-204, 1995). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of antibodies may be separately synthesized and combined using chemical methods to produce a full-length molecule.
  • The antibodies of the present invention may be generated from parental antibodies. Parent antibodies may be selected from various antibodies capable of binding specific targets and well known in the art, such as, but not limited to, but are not limited to anti-TNF antibody, anti-IL-12 antibody; anti-IL-18 antibody, anti-C5, anti-CD147, anti-gp120, anti-CD11a, anti-CD18, anti-VEGF, anti-CD40L, anti-ICAM-1, anti-CD2, anti-EGFR, anti-TGF-beta 2, anti-E-selectin, anti-Her2/neu, anti-CD14, anti-ICAM-3, anti-CD80, anti-CD4, anti-CD3, anti-CD23, anti-beta2-integrin, anti-CD52, anti-CD22, anti-CD20, anti-CD25, anti-CD33, anti-HLA, anti-IL-1alpha, anti-IL-1, anti-IL-1 receptor, anti-IL-2 receptor, anti-IL-4, anti-IL4 receptor, anti-IL5, anti-IL-5 receptor, anti-IL-6, anti-IL-8, anti-IL-9, anti-IL-13, anti-IL-13 receptor, anti-IL-17, and anti-IL-23. Parent antibodies may also be selected from various therapeutic antibodies including, but are not limited to, rituximab, trastuzumab, pertuzumab, cetuximab, alemtuzumab, muromonab, ibritumomab, gemtuzumab ozogamicin, alefacept, abciximab, basiliximab, palivizumab, infliximab, adalimumab, etanercept, natalizumab, bevacizumab, omalizumab, efalizumab, clenoliximab, labetuzumab, epratuzumab, and visilizumab.
  • The newly synthesized molecules may be substantially purified by preparative high performance liquid chromatography (see, e.g., Creighton, Proteins: Structures and Molecular Principles, WH Freeman and Co., New York, N.Y., 1983). The composition of a synthetic polypeptide may be confirmed by amino acid analysis or sequencing (e.g., using Edman degradation).
  • The present invention also relates to bispecific or bifunctional antibodies that have one binding site that specifically binds to a first antigen and a second binding site that specifically binds to a second antigen. This results in multi-functional valency, that is, an ability to bind at least two different epitopes simultaneously.
    • Polynucleotides Encoding Antibodies
  • The present invention also relates to polynucleotides encoding antibodies. These polynucleotides may be used, for example, to produce quantities of the antibodies for therapeutic or diagnostic use.
  • Polynucleotides of the present invention may also be isolated from host cells, free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides may be isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide may be used to obtain isolated polynucleotides encoding antibodies of the invention. For example, restriction enzymes and probes may be used to isolate polynucleotides which encode antibodies.
  • Antibody-encoding cDNA molecules may be made with standard molecular biology techniques, using mRNA as a template. Thereafter, cDNA molecules may be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook, et al., (Molecular Cloning: A Laboratory Manual, (Second Edition, Cold Spring Harbor Laboratory Press; Cold Spring Harbor, N.Y.; 1989) Vol. 1-3). An amplification technique, such as PCR, may be used to obtain additional copies of the polynucleotides. Alternatively, synthetic chemistry techniques may be used to synthesize polynucleotides encoding antibodies of the invention.
  • To express a polynucleotide encoding an antibody, the polynucleotide may be inserted into an expression vector that contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods that are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding antibodies and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook, et al. (1989) and in Ausubel, et al., (Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1995).
  • A variety of expression vector/host systems may be utilized to contain and express sequences encoding antibodies. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV); or bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.
  • The control elements or regulatory sequences are those non-translated regions of the vector—enhancers, promoters, 5′ and 3′ untranslated regions—which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters can be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses may be used. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding an antibody, vectors based on SV40 or EBV may be used with an appropriate selectable marker.
  • General texts describing additional molecular biological techniques useful herein, including the preparation of antibodies include Berger and Kimmel (Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152, Academic Press, Inc.); Sambrook, et al., (Molecular Cloning: A Laboratory Manual, (Second Edition, Cold Spring Harbor Laboratory Press; Cold Spring Harbor, N.Y.; 1989) Vol. 1-3); Current Protocols in Molecular Biology, (F. M. Ausabel et al. [Eds.], Current Protocols, a joint venture between Green Publishing Associates, Inc. and John Wiley & Sons, Inc. (supplemented through 2000)); Harlow et al., (Monoclonal Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1988), Paul [Ed.]); Fundamental Immunology, (Lippincott Williams & Wilkins (1998)); and Harlow, et al., (Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1998)).
    • Assays
  • The affinity (Kd) of antibody binding to an antigen may be assayed using any method known in the art including, for example, immunoassays such as enzyme-linked immunospecific assay (ELISA), Bimolecular Interaction Analysis (BIA) (see, e.g., Sjolander and Urbaniczky, Anal. Chem. 63:2338-2345, 1991; Szabo, et al., Curr. Opin. Struct. Biol. 5:699-705, 1995), and fluorescence-activated cell sorting (FACS) for quantification of antibody binding to cells that express an antigen. BIA is a technology for analyzing biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) may be used as an indication of real-time reactions between biological molecules.
  • The present invention also relates to the use of quantitative immunoassays to measure levels of proteins in patient samples. Many formats may be adapted for use with the methods of the present invention. For example, the detection and quantitation of a protein in patient samples may be performed, by enzyme-linked immunosorbent assays, radioimmunoassays, dual antibody sandwich assays, agglutination assays, fluorescent immunoassays, immunoelectron and scanning microscopy, among other assays commonly known in the art. The quantitation of a protein in such assays may be adapted by conventional methods known in the art. Serial changes in circulating a protein levels may be detected and quantified by a sandwich assay in which the capture antibody has been immobilized using conventional techniques on the surface of the support.
  • Suitable supports include, for example, synthetic polymer supports, such as polypropylene, polystyrene, substituted polystyrene, polyacrylamides (such as polyamides and polyvinylchloride), glass beads, agarose, and nitrocellulose.
  • The antibodies useful to identify proteins may be labeled in any conventional manner. An example of a label is horseradish peroxidase, and an example of a method of labeling antibodies is by using biotin-strepavidin complexes.
  • As appropriate, antibodies used in the immunoassays of this invention that are used as tracers may be labeled in any manner, directly or indirectly, that results in a signal that is visible or can be rendered visible. Detectable marker substances include radionuclides, such as 3H, 125I, and 131I; fluorescers, such as, fluorescein isothiocyanate and other fluorochromes, phycobiliproteins, phycoerythin, rare earth chelates, Texas red, dansyl and rhodamine; colorimetric reagents (chromogens); electron-opaque materials, such as colloidal gold; bioluminescers; chemiluminescers; dyes; enzymes, such as, horseradish peroxidase, alkaline phosphatases, glucose oxidase, glucose-6-phosphate dehydrogenase, acetylcholinesterase, alpha-, beta-galactosidase, among others; coenzymes; enzyme substrates; enzyme cofactors; enzyme inhibitors; enzyme subunits; metal ions; free radicals; or any other immunologically active or inert substance which provides a means of detecting or measuring the presence or amount of immunocomplex formed. Exemplary of enzyme substrate combinations are horseradish peroxidase and tetramethyl benzidine (TMB), and alkaline phosphatases and paranitrophenyl phosphate (pNPP).
  • Another detection and quantitation systems according to this invention produce luminescent signals, bioluminescent (BL) or chemiluminescent (CL). In chemiluminescent (CL) or bioluminescent (BL) assays, the intensity or the total light emission is measured and related to the concentration of the unknown analyte. Light can be measured quantitatively using a luminometer (photomultiplier tube as the detector) or charge-coupled device, or qualitatively by means of photographic or X-ray film. The main advantages of using such assays is their simplicity and analytical sensitivity, enabling the detection and/or quantitation of very small amounts of analyte.
  • Exemplary luminescent labels are acridinium esters, acridinium sulfonyl carboxamides, luminol, umbelliferone, isoluminol derivatives, photoproteins, such as aequorin, and luciferases from fireflies, marine bacteria, Vargulla and Renilla. Luminol can be used optionally with an enhancer molecule such as 4-iodophenol or 4-hydroxy-cinnamic acid. Typically, a CL signal is generated by treatment with an oxidant under basic conditions.
  • Additional luminescent detection systems are those wherein the signal (detectable marker) is produced by an enzymatic reaction upon a substrate. CL and BL detection schemes have been developed for assaying alkaline phosphatases (AP), glucose oxidase, glucose 6-phosphate dehydrogenase, horseradish peroxidase (HRP), and xanthine-oxidase labels, among others. AP and HRP are two enzyme labels which can be quantitated by a range of CL and BL reactions. For example, AP can be used with a substrate, such as an adamantyl 1,2-dioxetane aryl phosphate substrate (e.g. AMPPD or CSPD; Kricka, L. J., “Chemiluminescence and Bioluminescence, Analysis by,” Molecular Biology and Biotechnology: A Comprehensive Desk Reference (ed. R. A. Meyers) (VCH Publishers; N.Y., N.Y.; 1995)); for example, a disodium salt of 4-methoxy-4-(3-phosphatephenyl) spiro [1,2-dioxetane-3,2′-adamantane], with or without an enhancer molecule such as 1-(trioctylphosphonium methyl)-4-(tributylphosphonium methyl) benzene diochloride. HRP is may be used with substrates, such as, 2′,3′,6′-trifluorophenyl-methoxy-10-methylacridan-9-carboxylate.
  • CL and BL reactions may be adapted for analysis not only of enzymes, but also of other substrates, cofactors, inhibitors, metal ions, and the like. For example, luminol, firefly luciferase, and marine bacterial luciferase reactions are indicator reactions for the production or consumption of peroxide, ATP, and NADPH, respectively. They may be coupled to other reactions involving oxidases, kinases, and dehydrogenases, and may be used to measure any component of the coupled reaction (enzyme, substrate, cofactor).
  • The detectable marker may be directly or indirectly linked to an antibody used in an assay of this invention. Exemplary of an indirect linkage of the detectable label is the use of a binding pair between an antibody and a marker or the use of a signal amplification system.
  • Examples of binding pairs that may be used to link antibodies to detectable markers are biotin/avidin, streptavidin, or anti-biotin; avidin/anti-avidin; thyroxine/thyroxine-binding globulin; antigen/antibody; antibody/ anti-antibody; carbohydrate/lectins; hapten/anti-hapten antibody; dyes and hydrophobic molecules/hydrophobic protein binding sites; enzyme inhibitor, coenzyme or cofactor/enzyme; polynucleic acid/homologous polynucleic acid sequence; fluorescein/anti-fluorescein; dinitrophenol/anti-dinitrophenol; vitamin B12/intrinsic factor; cortisone, cortisol/cortisol binding protein; and ligands for specific receptor protein/membrane associated specific receptor proteins.
  • Various means for linking labels directly or indirectly to antibodies are known in the art. For example, labels may be bound either covalently or non-covalently. Exemplary antibody conjugation methods are described in Avarmeas, et al., Scan. J. Immunol. 8(Suppl. 7): 7, 1978); Bayer, et al., Meth. Enzymol. 62:308, 1979; Chandler, et al., J. Immunol. Meth. 53:187, 1982; Ekeke and Abuknesha, J. Steroid Biochem. 11:1579, 1979; Engvall and Perlmann, J. Immunol. 109:129, 1972; Geoghegan, et al., Immunol. Comm. 7:1, 1978; and Wilson and Nakane, Immunofluorescence and Related Techniques, Elsevier/North Holland Biomedical Press; Amsterdam (1978).
  • Depending upon the nature of the label, various techniques may be employed for detecting and quantitating the label. For fluorescers, a large number of fluorometers are available. For chemiluminescers, luminometers or films are available. With enzymes, a fluorescent, chemiluminescent, or colored product may be determined or measured fluorometrically, luminometrically, spectrophotometrically, or visually.
  • Various types of chemiluminescent compounds having an acridinium, benzacridinium, or acridan type of heterocyclic ring systems are other examples of labels. Examples of acridinium esters include those compounds having heterocyclic rings or ring systems that contain the heteroatom in a positive oxidation state including such ring systems as acridinium, benz[a]acridinium, benz[c]acridinium, benz[c]acridinium, a benzimidazole cation, quinolinium, isoquinolinium, quinolizinium, a cyclic substituted quinolinium, phenanthridinium, and quinoxalinium.
  • The tracer may be prepared by attaching to the selected antibody either directly or indirectly a reactive functional group present on the acridinium or benzacridinium ester, as is well known to those skilled in the art (see, e.g., Weeks, et al., Clin. Chem. 29(8):1474-1479, 1983). Examples of compounds are acridinium and benzacridinium esters with an aryl ring leaving group and the reactive functional group present in either the para or the meta position of the aryl ring. (see, e.g., U.S. Pat. No. 4,745,181 and WO 94/21823).
    • Methods of Use
  • As used herein, various terms are defined below.
  • The term “treatment” includes any process, action, application, therapy, or the like, wherein a subject (or patient), including a human being, is provided medical aid with the object of improving the subject's condition, directly or indirectly, or slowing the progression of a condition or disorder in the subject.
  • The term “combination therapy” or “co-therapy” means the administration of two or more therapeutic agents to treat a disease, condition, and/or disorder. Such administration encompasses co-administration of two or more therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each inhibitor agent. In addition, such administration encompasses use of each type of therapeutic agent in a sequential manner.
  • The antibodies of the inventin may be administered in combination with the following agents: cytotoxic agent, angiogenesis inhibitors, antirheumatic agent, muscle relaxant, narcotic, non-steroid anti-inflammatory drug, analgesic, anesthetic, sedative, local anesthetic, neuromuscular blocker, antimicrobial agent, immunoglobulins, antidepressant, asthma medication, cytokine, and cytokine antagonist.
  • For example, the antibodies of the inventin may be administered in combination with various anti-cancer agents including, but not limited to, bleomycin, docetaxel, doxorubicin, edatrexate, erlotinib, etoposide, finasteride, flutamide, gemcitabine, genitinib, goserelin acetate, granisetron, imatinib, irinotecan, ondansetron, paclitaxel, pegaspargase, pilocarpine hydrochloride, porfimer sodium, interleukin-2, rituximab, topotecan, trastuzumab, triapine, vincristine, and vinorelbine tartrate, or therapeutic antibodies or fragments thereof, or anti-angiogenic agent, such as, for example, angiostatin, bevacizumab, sorafenib, baculostatin, canstatin, maspin, anti-VEGF antibodies or peptides, anti-placental growth factor antibodies or peptides, anti-Flk-1 antibodies, anti-Fit-1 antibodies or peptides, laminin peptides, fibronectin peptides, plasminogen activator inhibitors, tissue metalloproteinase inhibitors, interferons, interleukin 12, IP-IO, Gro-β, thrombospondin, 2- methoxyoestradiol, proliferin-related protein, carboxiamidotriazole, CMIOI, Marimastat, pentosan polysulphate, angiopoietin 2, interferon-alpha, herbimycin A, PNU145156E, 16K prolactin fragment, Linomide, thalidomide, pentoxifylline, genistein, TNP-470, endostatin, paclitaxel, accutin, cidofovir, vincristine, bleomycin, AGM-1470, platelet factor 4 or minocycline.
  • The phrase “therapeutically effective” means the amount of each agent administered that will achieve the goal of improvement in a disease, condition, and/or disorder severity, while avoiding or minimizing adverse side effects associated with the given therapeutic treatment.
  • The term “pharmaceutically acceptable” means that the subject item is appropriate for use in a pharmaceutical product.
  • The antibodies of this invention are expected to be valuable as therapeutic agents. Accordingly, an embodiment of this invention includes a method of treating the various conditions in a patient (including mammals) which comprises administering to said patient a composition containing an amount of an antibody of the invention that is effective in treating the target condition.
  • The antibodies of the present invention may be used in the treatment or prevention of various diseases including, but not limited to, cancer, infectious disease, and autoimmune diseases.
  • The antibodies of the present invention or compositions including the antibodies may include a cytotoxic agent (e.g., monomethylauristatin-E) that is conjugated to the antibody.
  • Antibodies of the present invention may be administered alone or in combination with one or more additional therapeutic agents. Combination therapy includes administration of a single pharmaceutical dosage formulation which contains an antibody of the present invention and one or more additional therapeutic agents, as well as administration of the antibody of the present invention and each additional therapeutic agents in its own separate pharmaceutical dosage formulation. For example, an antibody of the present invention and a therapeutic agent may be administered to the patient together in a single oral dosage composition or each agent may be administered in separate oral dosage formulations.
  • Where separate dosage formulations are used, the antibody of the present invention and one or more additional therapeutic agents may be administered at essentially the same time (e.g., concurrently) or at separately staggered times (e.g., sequentially).
  • To assess the ability of a particular antibody to be therapeutically useful to treat cancer, as an example, the antibody may be tested in vivo in a mouse xenograft tumor model. An example of a therapeutic model is detailed in Example 8.
    • Pharmaceutical Compositions
  • The antibodies described herein may be provided in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be non-pyrogenic. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. A variety of aqueous carriers may be employed including, but not limited to saline, glycine, or the like. These solutions are sterile and generally free of particulate matter. These solutions may be sterilized by conventional, well known sterilization techniques (e.g., filtration). The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, and the like. The concentration of the antibody of the invention in such pharmaceutical formulation may vary widely, and may be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of administration selected. If desired, more than one type of antibody may be included in a pharmaceutical composition.
  • The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations which may be used pharmaceutically. Pharmaceutical compositions of the invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means.
  • Formulations suitable for subcutaneous, intravenous, intramuscular, and the like; suitable pharmaceutical carriers; and techniques for formulation and administration may be prepared by any of the methods well known in the art (see, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 20th edition, 2000).
    • Diagnostic Methods
  • The present invention also provides diagnostic methods with which a particular antigen may be detected in a patient sample or biological sample. Such diagnostic methods may be used, for example, to diagnose disorders in which a particular antigen is elevated or reduced. Such disorders include, but are not limited to, cancer, infectious disease, and autoimmune diseases. As an example, when used for diagnosis, detection of an amount of the antibody-antigen complex in a sample from a patient which is greater than an amount of the complex in a normal sample identifies the patient as likely to have the disorder
  • The patient sample may be contacted with an antibody of the invention, and the patient sample may then be assayed for the presence of an antibody-antigen complex. As described above, the antibody may comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • Optionally, the antibody may be bound to a solid support, which may accommodate automation of the assay. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art may be used to attach the antibody to the solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached to the antibody and the solid support. Binding of antigen and the antibody may be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.
    • Determination of a Therapeutically Effective Dose
  • The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to the amount of an antibody that may be used to effectively treat a disease (e.g., cancer) compared with the efficacy that is evident in the absence of the therapeutically effective dose.
  • The therapeutically effective dose may be estimated initially in animal models (e.g., rats, mice, rabbits, dogs, or pigs). The animal model may also be used to determine the appropriate concentration range and route of administration. Such information may then be used to determine useful doses and routes for administration in humans.
  • Therapeutic efficacy and toxicity (e.g., ED50—the dose therapeutically effective in 50% of the population and LD50—the dose lethal to 50% of the population) of an antibody may be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it may be expressed as the ratio, LD50/ED50. The data obtained from animal studies may used in formulating a range of dosage for human use. The dosage contained in such compositions may be within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • The exact dosage may be determined by the practitioner, in light of factors related to the patient who requires treatment. Dosage and administration may be adjusted to provide sufficient levels of the antibody or to maintain the desired effect. Factors that may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Effective in vivo dosages of an antibody are in the range of about 5 μg to about 500 μg/kg of patient body weight.
  • The mode of administration of antibody-containing pharmaceutical compositions of the present invention may be any suitable route which delivers the antibody to the host. As an example, pharmaceutical compositions of the invention may be useful for parenteral administration (e.g., subcutaneous, intramuscular, intravenous, or intranasal administration).
  • All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples, which are provided for purposes of illustration only and are not intended to limit the scope of the invention.
    • EXAMPLES
  • In order that this invention may be better understood, the following examples are set forth. These examples are for the purpose of illustration only, and are not to be construed as limiting the scope of the invention in any manner. All publications mentioned herein are incorporated by reference in their entirety.
    • Example 1: Construction, Expression, and Purification of Fab-Like Antibody
  • Antibodies 3E10 and 19G9 recognize tissue factor (TF) and tumor-associated antigen RG1, respectively. These two antibodies were used to construct protease-regulated antibodies containing the protease site DDDDK (SEQ ID NO: 26) linker located between the antigen binding domains and constant region domain. Specifically, these antibodies contained VL-DDDDK-CL on the light chain and VH-DDDDK-CH1-Myc-His6 on the heavy chain, where the linker is cleavable by enterokinase, and Myc and His6 are tags for detection and purification. The DNA sequences for the two antibodies were cloned into bacterial expression vectors using standard molecular biology technologies, and the constructs were confirmed by DNA sequencing. Examples of plasmid are shown in FIGS. 8 and 9. The plasmid containing either 3E10 or 19G9 was expressed and purified from bacterial strain TG1. Briefly, a single colony of bacteria strain TG1 containing the antibody expression plasmid was selected and grown overnight in 8 ml of 2×YT medium in the presence of 34 μg/ml chloramphenicol and 1% glucose. A volume of culture (7 ml) was transferred to 250 ml fresh 2×YT medium containing 34 μg/ml chloramphenicol and 0.1% glucose. After 3 hours of incubation, 0.5 mM IPTG was added to induce Fab expression. The culture was incubated overnight at 25° C. Following incubation, the culture was centrifuged to pellet the bacterial cells, and the pellet was resuspended in a Bug Buster® lysis buffer (Novagen, Madison, Wis.). After centrifugation, the bacterial lysis supernatant was filtered, and the Fab fragments were affinity-purified through a Ni-NTA column (Qiagen, Valencia, Calif.) according to the manufacturer's instruction.
  • Other examples of protease-regulated antibodies were also constructed using tandem linked variable regions from 3E10 and 19G9. These antibodies contained, for example, VL3E10-DDDDK-VL19G9-CL on the light chain and VH3E10-DDDDK-VH19G9-CH1-Myc-His6 on the heavy chain, where the linker is cleavable by enterokinase, and Myc and His6 are tags for detection and purification. An antibody library was also constructed using the framework regions (FR), for example, FR4 of 3E10 and FR1 of 19G9 either intact or truncated. Several types of protease-regulated antibodies were screened from this library. The cloning, expression, and purification were performed as described above.
    • Example 2: Cloning and Expression of IgG-Like Antibodies
  • The expression vector pIE_SRgamma_fa contains cDNAs encoding the constant regions of human IgG1 (fa haplotype) and kappa chains, respectively. An overlap PCR was performed to link the variable regions of anti-TF antibody 3E10 and anti-RG1 antibody 19G9. The native signal peptide of 19G9 was used for secretion of the protease-regulated antibodies. Four examples of peptide linkers located between the variable regions of 3E10 and 19G9 are Linker 1: SDDDDK (SEQ ID NO: 2), Linker 2: GGGGSDDDDK (SEQ ID NO: 3), Linker 3: GGGGSDDDDKGGGGS (SEQ ID NO: 4), and Linker 4: GGGGSGGGGSGGGGS (SEQ ID NO: 5). The primers for amplification of the variable region of the light chain introduced Hind III and Bsiw I sites into the 5′ and 3′ ends of PCR fragment, respectively. The resulting PCR-amplified VL genes were cloned into the HindIII/Bsiw site of pIE_SRgamma1_fa to create pIE-3E10VL-linker-19G9VL. The same strategy was used to clone in frame VH fusions of 3E10 and 19G9 (including linkers 1-4) into pIE-3E10VL-linker-19G9VL. Briefly, the primer pairs of the variable regions of 3E10 and 19G9 contained NotI/ApaI sites. The PCR products were digested with NotI/ApaI and inserted upstream of the CH region of pIE-3E1OVH-linker-19G9VH ensuring that the VH regions were in frame with the CH region in the respective pIE derivatives. The fmal constructs were verified by DNA sequencing analysis.
  • Transfection and transient expression of the protease-regulated antibodies were conducted using mammalian cells. Approximately 4×108 CHO-S cells supplemented with CHO-SF medium were prepared for transfection. Transfection was carried out using Lipofectamine™ 2000 (Invitrogen, Carlsbad, Calif.) and 1 mg plasmid DNA following the manufacturer's instruction. The cells were grown for three days after transfection, and the culture media was harvested and filtered for antibody isolation and purification.
  • Examples of the protease-regulated antibodies are described in Tables 3-9
  • TABLE 3 
    PROTEASE-REGULATED ANTIBODIES (Type 1)
    Fab-like protease-regulated antibodies against TF (3E10)
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA DLVESGGTLVQPGGSLRLSCAASGFSFTDAW
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP MSWVRQAPGKELEWVSSISGSGGSTYYAGSV
    DRFSGSIDTSSNSASLTISGLKTEDEADYY KGRFTISRDNSKNTLYLQMNSLRAEDTAVYY
    CQSYDSNNLVVFGGGTKLTVLGAGGGGSDD CARVLSLTDYYWYGMDVWGQGTLVTVSASDD
    DDKRTVAAPSVFIFPPSDEQLKSGTASVVC DDKSSASTKGPSVFPLAPSSKSTSGGTAALG
    LLNNFYPREAKVQWKVDNALQSGNSQESVT CLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
    EQDSKDSTYSLSSTLTLSKADYEKHKVYAC QSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
    EVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 33) PSNTKVDKKVEPKCEF (SEQ ID NO: 34)
    Fab-like protease-regulated antibodies against RG1 (19G9)
    Light chain Heavy chain
    DIVLTQSPGTLSLSPGERATLSCRASQSVSS QLVQSGGGLVQPGGSLRLSCAGSGFTFSSYV
    SYLAWYQQKPGQAPRLLIYGASSRATGIPDR MHWLRQAPGKGLEWVSVIGTGGVTHYADSVK
    FSGSGSGTDFTLTISRLEPEDFAVYYCQQYS GRFTISRDNAKNSLYLQMNSLRAEDTAVYYC
    SSLTFGGGTKVEIKDDDDKRTVAAPSVFIFP ARWGYYGSGSYENDAFDIWGQGTMVTVDDDD
    PSDEQLKSGTASVVCLLNNFYPREAKVQWKV KSSASTKGPSVFPLAPSSKSTSGGTAALGCL
    DNALQSGNSQESVPEQDSKDSTYSLSSTLTL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
    SKADYEKHKVYACEVTHQGLSSPVTKSFNRG SGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
    EC (SEQ ID NO: 35) NTKVDKKVEPKCEF (SEQ ID NO: 36)
    IgG-like protease-regulated antibodies against TF (3E10)
    Light chain Heavy chain
    NFMLTQPHSVSASPGKTVTISCTRSSGSVAS QVNLRESGGTLVQPGGSLRLSCAASGFSFTD
    YYVQWYQQRPGSSPTTVIYEDNHRPSGVPDR AWMSWVRQAPGKELEWVSSISGSGGSTYYAG
    FSGSIDTSSNSASLTISGLKTEDEADYYCQS SVKGRFTISRDNSKNTLYLQMNSLRAEDTAV
    YDSNNLVVFGGGTKLTVLGQSDDDDKPKAAP YYCARVLSLTDYYWYGMDVWGQGTLVTVSAS
    SVTLFPPSSEELQANKATLVCLISDFYPGAV DDDDKTKGPSVFPLAPSSKSTSGGTAALGCL
    TVAWKADSSPVKAGVETTTPSKQSNNKYAAS VKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
    SYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV SGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
    APTECS(SEQ ID NO: 37) NTKVDKRVEPKSCDKTHTCPPCPAPELLGGP
    SVFLFPPKPKDTLMISRTPEVTCVVVDVSHE
    DPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
    RVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
    IEKTISKAKGQPREPQVYTLPPSREEMTKNQ
    VSLTCLVKGFYPSDIAVEWESNGQPENNYKT
    TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
    CSVMHEALHNHYTQKSLSLSPGK
    (SEQ ID NO: 38)
    IgG-like protease-regulated antibodies against RG1 (19G9)
    Light chain Heavy chain
    EIVLTQSPGTLSLSPGERATLSCRASQSVS EVQLVQSGGGLVQPGGSLRLSCAGSGFTFS
    SSYLAWYQQKPGQAPRLLIYGASSRATGIP SYVMHWLRQAPGKGLEWVSVIGTGGVTHYA
    DRFSGSGSGTDFTLTISRLEPEDFAVYYCQ DSVKGRFTISRDNAKNSLYLQMNSLRAEDT
    QYSSSLTFGGGTKVEIKRTSDDDDKVAAPS AVYYCARWGYYGSGSYENDAFDIWGQGTMV
    VFIFPPSDEQLKSGTASVVCLLNNFYPREA TVSSASDDDDDKTKGPSVFPLAPSSKSTSG
    KVQWKVDNALQSGNSQESVTEQDSKDSTYS GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    LSSTLTLSKADYEKHKVYACEVTHQGLSSP HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    VTKSFNRGEC YICNVNHKPSNTKVDKRVEPKSCDKTHTCP
    (SEQ ID NO: 39) PCPAPELLGGPSVFLFPPKPKDTLMISRTP
    EVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
    KTKPREEQYNSTYRVVSVLTVLHQDWLNGK
    EYKCKVSNKALPAPIEKTISKAKGQPREPQ
    VYTLPPSREEMTKNQVSLTCLVKGFYPSDI
    AVEWESNGQPENNYKTTPPVLDSDGSFFLY
    SKLTVDKSRWQQGNVFSCSVMHEALHNHYT
    QKSLSLSPGK (SEQ ID NO: 40)
  • TABLE 4
    PROTEASE-REGULATED ANTIBODIES (Type 2)
    Fab-like protease-regulated antibodies against TF and RG1
    H1L1
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKE TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    IVLTQSPGTLSLSPGERATLSCRASQSVSS VSASDDDDKEVQLVQSGGGLVQPGGSLRLS
    SYLAWYQQKPGQAPRLLIYGASSRATGIPD CAGSGFTFSSYVMHWLRQAPGKGLEWVSVI
    RFSGSGSGTDFTLTISRLEPEDFAVYYCQQ GTGGVTHYADSVKGRFTISRDNAKNSLYLQ
    YSSSLTFGGGTKVEIKRTVAAPSVFIFPPS MNSLRAEDTAVYYCARWGYYGSGSYENDAF
    DEQLKSGTASVVCLLNNFYPREAKVQWKVD DIWGQGTMVTVSSASTKGPSVFPLAPSSKS
    NALQSGNSQESVTEQDSKDSTYSLSSTLTL TSGGTAALGCLVKDYFPEPVTVSWNSGALT
    SKADYEKHKVYACEVTHQGLSSPVTKSFNR SGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    GEC (SEQ ID NO: 41) TQTYICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 42)
    H1L4
    Light chain Heavy chain
    DTVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKL TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    TQSPGTLSLSPGERATLSCRASQSVSSSYL VSASDDDDKEVQLVQSGGGLVQPGGSLRLS
    AWYQQKPGQAPRLLIYGASSRATGIPDRFS CAGSGFTFSSYVMHWLRQAPGKGLEWVSVI
    GSGSGTDFTLTISRLEPEDFAVYYCQQYSS GTGGVTHYADSVKGRFTISRDNAKNSLYLQ
    SLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ MNSLRAEDTAVYYCARWGYYGSGSYENDAF
    LKSGTASVVCLLNNFYPREAKVQWKVDNAL DIWGQGTMVTVSSASTKGPSVFPLAPSSKS
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKA TSGGTAALGCLVKDYFPEPVTVSWNSGALT
    DYEKHKVYACEVTHQGLSSPVTKSFNRGEC SGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    (SEQ ID NO: 43) TQTYICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 44)
    H1L7
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKS TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    PGTLSLSPGERATLSCRASQSVSSSYLAWY VSASDDDDKEVQLVQSGGGLVQPGGSLRLS
    QQKPGQAPRLLIYGASSRATGIPDRFSGSG CAGSGFTFSSYVMHWLRQAPGKGLEWVSVI
    SGTDFTLTISRLEPEDFAVYYCQQYSSSLT GTGGVTHYADSVKGRFTISRDNAKNSLYLQ
    FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS MNSLRAEDTAVYYCARWGYYGSGSYENDAF
    GTASVVCLLNNFYPREAKVQWKVDNALQSG DIWGQGTMVTVSSASTKGPSVFPLAPSSKS
    NSQESVTEQDSKDSTYSLSSTLTLSKADYE TSGGTAALGCLVKDYFPEPVTVSWNSGALT
    KHKVYACEVTHQGLSSPVTKSFNRGEC SGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    (SEQ ID NO: 45) TQTYICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 46)
    H4L2
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKEIV TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    LTQSPGTLSLSPGERATLSCRASQSVSSSY VDDDDKQSGGGLVQPGGSLRLSCAGSGFTF
    LAWYQQKPGQAPRLLIYGASSRATGIPDRF SSYVMHWLRQAPGKGLEWVSVIGTGGVTHY
    SGSGSGTDFTLTISRLEPEDFAVYYCQQYS ADSVKGRFTISRDNAKNSLYLQMNSLRAED
    SSLTFGGGTKVEIKRTVAAPSVFIFPPSDE TAVYYCARWGYYGSGSYENDAFDIWGQGTM
    QLKSGTASVVCLLNNFYPREAKVQWKVDNA VTVSSASTKGPSVFPLAPSSKSTSGGTAAL
    LQSGNSQESVTEQDSKDSTYSLSSTLTLSK GCLVKDYFPEPVTVSWNSGALTSGVHTFPA
    ADYEKHKVYACEVTHQGLSSPVTKSFNRGE VLQSSGLYSLSSVVTVPSSSLGTQTYICNV
    C (SEQ ID NO: 47) NHKPSNTKVDKKVEPKCEF (SEQ ID NO: 48)
    H4L5
    Light chain Heavy chain
    DIVLTOPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKLTQ TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    SPGTLSLSPGERATLSCRASQSVSSSYLAW VDDDDKQSGGGLVQPGGSLRLSCAGSGFTF
    YQQKPGQAPRLLIYGASSRATGIPDRFSGS SSYVMHWLRQAPGKGLEWVSVIGTGGVTHY
    GSGTDFTLTISRLEPEDFAVYYCQQYSSSL ADSVKGRFTISRDNAKNSLYLQMNSLRAED
    TFGGGTKVEIKRTVAAPSVFIFPPSDEQLK TAVYYCARWGYYGSGSYENDAFDIWGQGTM
    SGTASVVCLLNNFYPREAKVQWKVDNALQS VTVSSASTKGPSVFPLAPSSKSTSGGTAAL
    GNSQESVTEQDSKDSTYSLSSTLTLSKADY GCLVKDYFPEPVTVSWNSGALTSGVHTFPA
    EKHKVYACEVTHQGLSSPVTKSFNRGEC VLQSSGLYSLSSVVTVPSSSLGTQTYICNV
    (SEQ ID NO: 49) NHKPSNTKVDKKVEPKCEF (SEQ ID NO: 50)
    H4L7
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKS TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    PGTLSLSPGERATLSCRASQSVSSSYLAWY VDDDDKQSGGGLVQPGGSLRLSCAGSGFTF
    QQKPGQAPRLLIYGASSRATGIPDRFSGSG SSYVMHWLRQAPGKGLEWVSVIGTGGVTHY
    SGTDFTLTISRLEPEDFAVYYCQQYSSSLT ADSVKGRFTISRDNAKNSLYLQMNSLRAED
    FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS TAVYYCARWGYYGSGSYENDAFDIWGQGTM
    GTASVVCLLNNFYPREAKVQWKVDNALQSG VTVSSASTKGPSVFPLAPSSKSTSGGTAAL
    NSQESVTEQDSKDSTYSLSSTLTLSKADYE GCLVKDYFPEPVTVSWNSGALTSGVHTFPA
    KHKVYACEVTHQGLSSPVTKSFNRGEC VLQSSGLYSLSSVVTVPSSSLGTQTYICNV
    (SEQ ID NO: 51) NHKPSNTKVDKKVEPKCEF (SEQ ID NO: 52)
    H5L5
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKLTQ TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    SPGTLSLSPGERATLSCRASQSVSSSYLAW VSASDDDDKLVQPGGSLRLSCAGSGFTFSS
    YQQKPGQAPRLLIYGASSRATGIPDRFSGS YVMHWLRQAPGKGLEWVSVIGTGGVTHYAD
    GSGTDFTLTISRLEPEDFAVYYCQQYSSSL SVKGRFTISRDNAKNSLYLQMNSLRAEDTA
    TFGGGTKVEIKRTVAAPSVFIFPPSDEQLK VYYCARWGYYGSGSYENDAFDIWGQGTMVT
    SGTASVVCLLNNFYPREAKVQWKVDNALQS VSSASTKGPSVFPLAPSSKSTSGGTAALGC
    GNSQESVTEQDSKDSTYSLSSTLTLSKADY LVKDYFPEPVTVSWNSGALTSGVHTFPAVL
    EKHKVYACEVTHQGLSSPVTKSFNRGEC QSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    (SEQ ID NO: 53) KPSNTKVDKKVEPKCEF (SEQ ID NO: 54)
  • TABLE 5
    PROTEASE-REGULATED ANTIBODIES (Type 2)
    IgG-like protease-regulated antibodies against TF and RG1
    3E10-Linker1-19G9
    Light chain Heavy chain
    NFMLTQPHSVSASPGKTVTISCTRSSGSVA  QVNLRESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQNNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKE TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    IVLTQSPGTLSLSPGERATLSCRASQSVSS VSASDDDDKEVQLVQSGGGLVQPGGSLRLS
    SYLAWYQQKPGQAPRLLIYGASSRATGIPD CAGSGFTFSSYVMHWLRQAPGKGLEWVSVI
    RFSGSGSGTDFTLTISRLEPEDFAVYYCQQ GTGGVTHYADSVKGRFTISRDNAKNSLYLQ
    YSSSLTFGGGTKVEIKRTVAAPSVFIFPPS MNSLRAEDTAVYYCARWGYYGSGSYENDAF
    DEQLKSGTASVVCLLNNFYPREAKVQWKVD DIWGQGTMVTVSSASTKGPSVFPLAPSSKS
    NALQSGNSQESVTEQDSKDSTYSLSSTLTL TSGGTAALGCLVKDYFPEPVTVSWNSGALT
    SKADYEKHKVYACEVTHQGLSSPVTKSFNR SGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    GEC (SEQ ID NO: 55) TQTYICNVNHKPSNTKVDKRVEPKSCDKTH
    TCPPCPAPELLGGPSVFLFPPKPKDTLMIS
    RTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
    HNAKTKPREEQYNSTYRVVSVLTVLHQDWL
    NGKEYKCKVSNKALPAPIEKTISKAKGQPR
    EPQVYTLPPSREEMTKNQVSLTCLVKGFYP
    SDIAVEWESNGQPENNYKTTPPVLDSDGSF
    FLYSKLTVDKSRWQQGNVFSCSVMHEALHN
    HYTQKSLSLSPGK (SEQ ID NO: 56)
    3E10-Linker2-19G9
    Light chain Heavy chain
    NFMLTQPHSVSASPGKTVTISCTRSSGSVA QVNLRESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGAGGGGSDD TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    DDKEIVLTQSPGTLSLSPGERATLSCRASQ VSAGGGGSDDDDKEVQLVQSGGGLVQPGGS
    SVSSSYLAWYQQKPGQAPRLLIYGASSRAT LRLSCAGSGFTFSSYVMHWLRQAPGKGLEW
    GIPDRFSGSGSGTDFTLTISRLEPEDFAVY VSVIGTGGVPHYADSVKGRFTISRDNAKNS
    YCQQYSSSLTFGGGTKVEIKRTVAAPSVFI LYLQMNSLRAEDTAVYYCARWGYYGSGSYE
    FPPSDEQLKSGTASVVCLLNNFYPREAKVQ NDAFDIWGQGTMVTVSSASTKGPSVFPLAP
    WKVDNALQSGNSQESVTEQDSKDSTYSLSS SSKSTSGGTAALGCLVKDYFPEPVTVSWNS
    TLTLSKADYEKHKVYACEVTHQGLSSPVTK GALTSGVHTFPAVLQSSGLYSLSSVVTVPS
    SFNRGEC (SEQ ID NO: 57) SSLGTQTYICNVNHKPSNTKVDKRVEPKSC
    DKTHTCPPCPAPELLGGPSVFLFPPKPKDT
    LMISRTPEVTCVVVDVSHEDPEVKFNWYVD
    GVEVHNAKTKPREEQYNSTYRVVSVLTVLH
    QDWLNGKEYKCKVSNKALPAPIEKTISKAK
    GQPREPQVYTLPPSREEMTKNQVSLTCLVK
    GFYPSDIAVEWESNGQPENNYKTTPPVLDS
    DGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
    ALHNHYTQKSLSLSPGK (SEQ ID NO: 58)
    3E10-Linker3-19G9
    Light chain Heavy chain
    NFMLTQPHSVSASPGKTVTISCTRSSGSVA  QVNLRESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGAGGGGSDD TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    DDKGGGGSEIVLTQSPGTLSLSPGERATLS VSAGGGGSDDDDKGGGGSEVQLVQSGGGLV
    CRASQSVSSSYLAWYQQKPGQAPRLLIYGA QPGGSLRLSCAGSGFTFSSYVMHWLRQAPG
    SSRATGIPDRFSGSGSGTDFTLTISRLEPE KGLEWVSVIGTGGVTHYADSVKGRFTISRD
    DFAVYYCQQYSSSLTFGGGTKVEIKRTVAA NAKNSLYLQMNSLRAEDTAVYYCARWGYYG
    PSVFIFPPSDEQLKSGTASVVCLLNNFYPR SGSYENDAFDIWGQGTMVTVSSASTKGPSV
    EAKVQWKVDNALQSGNSQESVTEQDSKDST FPLAPSSKSTSGGTAALGCLVKDYFPEPVT
    YSLSSTLTLSKADYEKHKVYACEVTHQGLS VSWNSGALTSGVHTFPAVLQSSGLYSLSSV
    SPVTKSFNRGEC (SEQ ID NO: 59) VTVPSSSLGTQTYICNVNHKPSNTKVDKRV
    EPKSCDKTHTCPPCPAPELLGGPSVFLFPP
    KPKDTLMISRTPEVTCVVVDVSHEDPEVKF
    NWYVDGVEVHNAKTKPREEQYNSTYRVVSV
    LTVLHQDWLNGKEYKCKVSNKALPAPIEKT
    ISKAKGQPREPQVYTLPPSREEMTKNQVSL
    TCLVKGFYPSDIAVEWESNGQPENNYKTTP
    PVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
    SVMHEALHNHYTQKSLSLSPGK 
    (SEQ ID NO: 60)
    3E10-Linker4-19G9
    Light chain Heavy chain
    NFMLTQPHSVSASPGKTVTISCTRSSGSVASYYVQ QVNLRESGGTLVQPGGSLRLSCAASGFSFTDAWMS
    WYQQRPGSSPTTVIYEDNHRPSGVPDRFSGSIDTS WVRQAPGKELEWVSSISGSGGSTYYAGSVKGRFTI
    SNSASLTISGLKTEDEADYYCQSYDSNNLVVFGGG SRDNSKNTLYLQMNSLRAEDTAVYYCARVLSLTDY
    TKLTVLGAGGGGSGGGGSGGGGSEIVLTQSPGTLS YWYGMDVWGQGTLVTVSAGGGGSGGGGSGGGGSEV
    LSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRL QLVQSGGGLVQPGGSLRLSCAGSGFTFSSYVMHWL
    LIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPE RQAPGKGLEWVSVIGTGGVTHYADSVKGRFTISRD
    DFAVYYCQQYSSSLTFGGGTKVEIKRTVAAPSVFI NAKNSLYLQMNSLRAEDTAVYYCARWGYYGSGSYE
    FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN NDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKST
    ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
    KHKVYACEVTHQGLSSPVTKSFNRGEC PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK
    (SEQ ID NO: 61) PSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSV
    FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
    NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
    QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE
    PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE
    WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
    RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    (SEQ ID NO: 62)
    3E10-Link1-19G9 Fab
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVASYYVQ QVQLVESGGTLVQPGGSLRLSCAASGFSFTDAWMS
    WYQQRPGSSPTTVIYEDNHRPSGVPDRFSGSIDTS WVRQAPGKELEWVSSISGSGGSTYYAGSVKGRFTI
    SNSASLTISGLKTEDEADYYCQSYDSNNLVVFGGG SRDNSKNTLYLQMNSLRAEDTAVYYCARVLSLTDY
    TKLTVLGASDDDDKEIVLTQSPGTLSLSPGERATL YWYGMDVWGQGTLVITSASDDDDKEVQLVQSGGGL
    SCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRA VQPGGSLRLSCAGSGFTFSSYVMHWLRQAPGKGLE
    TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQ WVSVIGTGGVTHYADSVKGRFTISRDNAKNSLYLQ
    YSSSLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLK MNSLRAEDTAVYYCARWGYYGSGSYENDAFDIWGQ
    SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE  GTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
    SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
    THQGLSSPVTKSFNRGEA YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK
    (SEQ ID NO: 63) VEPKSEF (SEQ ID NO: 64)
  • TABLE 6
    PROTEASE-REGULATED ANTIBODIES (Type 3)
    Fab-like protease-regulated antibodies
    H1L5
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKLTQ TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    SPGTLSLSPGERATLSCRASQSVSSSYLAW VSASDDDDKEVQLVQSGGGLVQPGGSLRLS
    YQQKPGQAPRLLIYGASSRATGIPDRFSGS CAGSGFTFSSYVMHWLRQAPGKGLEWVSVI
    GSGTDFTLTISRLEPEDFAVYYCQQYSSSL GTGGVTHYADSVKGRFTISRDNAKNSLYLQ
    TFGGGTKVEIKRTVAAPSVFIFPPSDEQLK MNSLRAEDTAVYYCARWGYYGSGSYENDAF
    SGTASVVCLLNNFYPREAKVQWKVDNALQS DIWGQGTMVTVSSASTKGPSVFPLAPSSKS
    GNSQESVTEQDSKDSTYSLSSTLTLSKADY TSGGTAALGCLVKDYFPEPVTVSWNSGALT
    EKHKVYACEVTHQGLSSPVTKSFNRGEC SGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    (SEQ ID NO: 65) TQTYICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 66)
    H2L1
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKE TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    IVLTQSPGTLSLSPGERATLSCRASQSVSS VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    SYLAWYQQKPGQAPRLLIYGASSRATGIPD SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    RFSGSGSGTDFTLTISRLEPEDFAVYYCQQ GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    YSSSLTFGGGTKVEIKRTVAAPSVFIFPPS LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    DEQLKSGTASVVCLLNNFYPREAKVQWKVD GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    NALQSGNSQESVTEQDSKDSTYSLSSTLTL GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    SKADYEKHKVYACEVTHQGLSSPVTKSFNR HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    GEC (SEQ ID NO: 67) YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 68)
    H2L2
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVICGRFTISRDNSKNTLYLONSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKEIV TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    LTQSPGTLSLSPGERATLSCRASQSVSSSY VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    LAWYQQKPGQAPRLLIYGASSRATGIPDRF SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    SGSGSGTDFTLTISRLEPEDFAVYYCQQYS GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    SSLTFGGGTKVEIKRTVAAPSVFIFPPSDE LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    QLKSGTASVVCLLNNFYPREAKVQWKVDNA GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    LQSGNSQESVTEQDSKDSTYSLSSTLTLSK GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    ADYEKHKVYACEVTHQGLSSPVTKSFNRGE HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    C (SEQ ID NO: 69) YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 70)
    H2L4
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGCGTKLTVLGASASDDDD TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    KLTQSPGTLSLSPGERATLSCRASQSVSSS VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    YLAWYQQKPGQAPRLLIYGASSRATGIPDR SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    FSGSGSGTDFTLTISRLEPEDFAVYYCQQY GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    SSSLTFGGGTKVEIKRTVAAPSVFIFPPSD LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    EQLKSGTASVVCLLNNFYPREAKVQWKVDN GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    ALQSGNSQESVTEQDSKDSTYSLSSTLTLS GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    KADYEKHKVYACEVTHQGLSSPVTKSFNRG HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    EC (SEQ ID NO: 71) YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 72)
    H2L5
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKLTQ TAVYYCARVLSLTDYYWYGNDVWGQGTLVT
    SPGTLSLSPGERATLSCRASQSVSSSYLAW VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    YQQKPGQAPRLLIYGASSRATGIPDRFSGS SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    GSGTDFTLTISRLEPEDFAVYYCQQYSSSL GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    TFGGGTKVEIKRTVAAPSVFIFPPSDEQLK LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    SGTASVVCLLNNFYPREAKVQWKVDNALQS GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    GNSQESVTEQDSKDSTYSLSSTLTLSKADY GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    EKHKVYACEVTHQGLSSPVTKSFNRGEC HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    (SEQ ID NO: 73) YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 74)
    H2L7
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKS TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    PGTLSLSPGERATLSCRASQSVSSSYLAWY VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    QQKPGQAPRLLIYGASSRATGIPDRFSGSG SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    SGTDFTLTISRLEPEDFAVYYCQQYSSSLT GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    GTASVVCLLNNFYPREAKVQWKVDNALQSG GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    NSQESVTEQDSKDSTYSLSSTLTLSKADYE GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    KHKVYACEVTHQGLSSPVTKSFNRGEC HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    (SEQ ID NO: 75) YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 76)
    H2L8
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKSPG TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    TLSLSPGERATLSCRASQSVSSSYLAWYQQ VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    KPGQAPRLLIYGASSRATGIPDRFSGSGSG SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    TDFTLTISRLEPEDFAVYYCQQYSSSLTFG GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    GGTKVEIKRTVAAPSVFIFPPSDEQLKSGT LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    ASVVCLLNNFYPREAKVQWKVDNALQSGNS GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    QESVTEQDSKDSTYSLSSTLTLSKADYEKH GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    KVYACEVTHQGLSSPVTKSFNRGEC HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    (SEQ ID NO: 77) YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 78)
  • TABLE 7
    PROTEASE-REGULATED ANTIBODIES(Type 3)
    IgG-like protease-regulated antibodies
    3E10-Linker1a-19G9
    Light chain Heavy chain
    NFMLTQPHSVSASPGKTVTISCTRSSGSVA QVNLRESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVSDDDDKEIVL TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    TQSPGTLSLSPGERATLSCRASQSVSSSYL VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    AWYQQKPGQAPRLLIYGASSRATGIPDRFS SGFTFSSYVMEWLRQAPGKGLEWVSVIGTG
    GSGSGTDFTLTISRLEPEDFAVYYCQQYSS GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    SLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    LKSGTASVVCLLNNFYPREAKVQWKVDNAL GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKA GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    DYEKHKVYACEVTHQGLSSPVTKSFNRGEC HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    (SEQ ID NO: 79) YICNVNHKPSNTKVDKRVEPKSCDKTHTCP
    PCPAPELLGGPSVFLFPPKPKDTLMISRTP
    EVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
    KTKPREEQYNSTYRVVSVLTVLHQDWLNGK
    EYKCKVSNKALPAPIEKTISKAKGQPREPQ
    VYTLPPSREEMTKNQVSLTCLVKGFYPSDI
    AVEWESNGQPENNYKTTPPVLDSDGSFFLY
    SKLTVDKSRWQQGNVFSCSVMHEALHNHYT
    QKSLSLSPGK (SEQ ID NO: 80)
    3E10-Linker1b-19G9
    Light chain Heavy chain
    NFMLTQPHSVSASPGKTVTISCTRSSGSVA QVNLRESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVSDDDDKLTQS TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    PGTLSLSPGERATLSCRASQSVSSSYLAWY VDDDDKQSGGGLVQPGGSLRLSCAGSGFTF
    QQKPGQAPRLLIYGASSRATGIPDRFSGSG SSYVMHWLRQAPGKGLEWVSVIGTGGVTHY
    SGTDFTLTISRLEPEDFAVYYCQQYSSSLT ADSVKGRFTISRDNAKNSLYLQMNSLRAED
    FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS TAVYYCARWGYYGSGSYENDAFDIWGQGTM
    GTASVVCLLNNFYPREAKVQWKVDNALQSG VTVSSASTKGPSVFPLAPSSKSTSGGTAAL
    NSQESVTEQDSKDSTYSLSSTLTLSKADYE GCLVKDYFPEPVTVSWNSGALTSGVHTFPA
    KHKVYACEVTHQGLSSPVTKSFNRGEC VLQSSGLYSLSSVVTVPSSSLGTQTYICNV
    (SEQ ID NO: 80) NHKPSNTKVDKRVEPKSCDKTHTCPPCPAP
    ELLGGPSVFLFPPKPKDTLMISRTPEVTCV
    VVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
    EEQYNSTYRVVSVLTVLHQDWLNGKEYKCK
    VSNKALPAPIEKTISKAKGQPREPQVYTLP
    PSREEMTKNQVSLTCLVKGFYPSDIAVEWE
    SNGQPENNYKTTPPVLDSDGSFFLYSKLTV
    DKSRWQQGNVFSCSVMHEALHNHYTQKSLS
    LSPGK (SEQ ID NO: 82)
    3E10-Linker1c-19G9
    Light chain Heavy chain
    NFMLTQPHSVSASPGKTVTISCTRSSGSVA QVNLRESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKL TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    TQSPGTLSLSPGERATLSCRASQSVSSSYL VSASDDDDKQSGGGLVQPGGSLRLSCAGSG
    AWYQQKPGQAPRLLIYGASSRATGIPDRFS FTFSSYVMHWLRQAPGKGLEWVSVIGTGGV
    GSGSGTDFTLTISRLEPEDFAVYYCQQYSS THYADSVKGRFTISRDNAKNSLYLQMNSLR
    SLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ AEDTAVYYCARWGYYGSGSYENDAFDIWGQ
    LKSGTASVVCLLNNFYPREAKVQWKVDNAL GTMVTVSSASTKGPSVFPLAPSSKSTSGGT
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKA AALGCLVKDYFPEPVTVSWNSGALTSGVHT
    DYEKHKVYACEVTHQGLSSPVTKSFNRGEC FPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
    (SEQ ID NO: 83) CNVNHKPSNTKVDKRVEPKSCDKTHTCPPC
    PAPELLGGPSVFLFPPKPKDTLMISRTPEV
    TCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
    KPREEQYNSTYRVVSVLTVLHQDWLNGKEY
    KCKVSNKALPAPIEKTISKAKGQPREPQVY
    TLPPSREEMTKNQVSLTCLVKGFYPSDIAV
    EWESNGQPENNYKTTPPVLDSDGSFFLYSK
    LTVDKSRWQQGNVFSCSVMHEALHNHYTQK
    SLSLSPGK (SEQ ID NO: 84)
  • TABLE 8
    PROTEASE-REGULATED ANTIBODIES (Type 4)
    H3L1
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKE TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    IVLTQSPGTLSLSPGERATLSCRASQSVSS VSASDDDDKQSGGGLVQPGGSLRLSCAGSG
    SYLAWYQQKPGQAPRLLIYGASSRATGIPD ETESSYVMHWLRQAPGKGLEWVSVIGTGGV
    RFSGSGSGTDFTLTISRLEPEDFAVYYCQQ THYADSVKGRFTISRDNAKNSLYLQMNSLR
    YSSSLTFGGGTKVEIKRTVAAPSVFIEPPS AEDTAVYYCARWGYYGSGSYENDAFDIWGQ
    DEQLKSGTASVVCLLNNFYPREAKVQWKVD GTMVTVSSASTKGPSVFPLAPSSKSTSGGT
    NALQSGNSQESVTEQDSKDSTYSLSSTLTL AALGCLVKDYFPEPVTVSWNSGALTSGVHT
    SKADYEKHKVYACEVTHQGLSSPVTKSFNR FPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
    GEC (SEQ ID NO: 85) CNVNHKPSNTKVDKKVEPKCEF (SEQ ID NO: 86)
    H3L2
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGESET
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKEIV TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    LTQSPGTLSLSPGERATLSCRASQSVSSSY VSASDDDDKQSGGGLVQPGGSLRLSCAGSG
    LAWYQQKPGQAPRLLIYGASSRATGIPDRF FTFSSYVMHWLRQAPGKGLEWVSVIGTGGV
    SGSGSGTDFTLTISRLEPEDFAVYYCQQYS THYADSVKGRFTISRDNAKNSLYLQMNSLR
    SSLTFGGGTKVEIKRTVAAPSVFIFPPSDE AEDTAVYYCARWGYYGSGSYENDAFDIWGQ
    QLKSGTASVVCLLNNFYPREAKVQWKVDNA GTMVTVSSASTKGPSVFPLAPSSKSTSGGT
    LQSGNSQESVTEQDSKDSTYSLSSTLTLSK AALGCLVKDYFPEPVTVSWNSGALTSGVHT
    ADYEKHKVYACEVTHQGLSSPVTKSFNRGE FPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
    C (SEQ ID NO: 87) CNVNHKPSNTKVDKKVEPKCEF (SEQ ID NO: 88)
    H3L4
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKL TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    TQSPGTLSLSPGERATLSCRASQSVSSSYL VSASDDDDKQSGGGLVQPGGSLRLSCAGSG
    AWYQQKPGQAPRLLIYGASSRATGIPDRFS FTFSSYVMHWLRQAPGKGLEWVSVIGTGGV
    GSGSGTDFTLTISRLEPEDFAVYYCQQYSS THYADSVKGRFTISRDNAKNSLYLQMNSLR
    SLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ AEDTAVYYCARWGYYGSGSYENDAFDIWGQ
    LKSGTASVVCLLNNFYPREAKVQWKVDNAL GTMVTVSSASTKGPSVFPLAPSSKSTSGGT
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKA AALGCLVKDYFPEPVTVSWNSGALTSGVHT
    DYEKHKVYACEVTHQGLSSPVTKSFNRGEC FPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
    (SEQ ID NO: 89) CNVNHKPSNTKVDKKVEPKCEF (SEQ ID NO: 90)
    H3L5
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKLTQ TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    SPGTLSLSPGERATLSCRASQSVSSSYLAW VSASDDDDKQSGGGLVQPGGSLRLSCAGSG
    YQQKPGQAPRLLIYGASSRATGIPDRFSGS FTFSSYVMHWLRQAPGKGLEWVSVIGTGGV
    GSGTDFTLTISRLEPEDFAVYYCQQYSSSL THYADSVKGRFTISRDNAKNSLYLQMNSLR
    TFGGGTKVEIKRTVAAPSVFIFPPSDEQLK AEDTAVYYCARWGYYGSGSYENDAFDIWGQ
    SGTASVVCLLNNFYPREAKVQWKVDNALQS GTMVTVSSASTKGPSVFPLAPSSKSTSGGT
    GNSQESVTEQDSKDSTYSLSSTLTLSKADY AALGCLVKDYFPEPVTVSWNSGALTSGVHT
    EKHKVYACEVTHQGLSSPVTKSFNRGEC FPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
    (SEQ ID NO: 91) CNVNHKPSNTKVDKKVEPKCEF (SEQ ID NO: 92)
    H3L7
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKS TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    PGTLSLSPGERATLSCRASQSVSSSYLAWY VSASDDDDKQSGGGLVQPGGSLRLSCAGSG
    QQKPGQAPRLLIYGASSRATGIPDRFSGSG FTFSSYVMHWLRQAPGKGLEWVSVIGTGGV
    SGTDFTLTISRLEPEDFAVYYCQQYSSSLT THYADSVKGRFTISRDNAKNSLYLQMNSLR
    FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS AEDTAVYYCARWGYYGSGSYENDAFDIWGQ
    GTASVVCLLNNFYPREAKVQWKVDNALQSG GTMVTVSSASTKGPSVFPLAPSSKSTSGGT
    NSQESVTEQDSKDSTYSLSSTLTLSKADYE AALGCLVKDYFPEPVTVSWNSGALTSGVHT
    KHKVYACEVTHQGLSSPVTKSFNRGEC FPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
    (SEQ ID NO: 93) CNVNHKPSNTIWDKKVEPKCEF (SEQ ID NO: 94)
    H1L2
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKEIV TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    LTQSPGTLSLSPGERATLSCRASQSVSSSY VSASDDDDKEVQLVQSGGGLVQPGGSLRLS
    LAWYQQKPGQAPRLLIYGASSRATGIPDRF CAGSGFTFSSYVMHWLRQAPGKGLEWVSVI
    SGSGSGTDFTLTISRLEPEDFAVYYCQQYS GTGGVTHYADSVKGRFTISRDNAKNSLYLQ
    SSLTFGGGTKVEIKRTVAAPSVFIFPPSDE MNSLRAEDTAVYYCARWGYYGSGSYENDAF
    QLKSGTASVVCLLNNFYPREAKVQWKVDNA DIWGQGTMVTVSSASTKGPSVFPLAPSSKS
    LQSGNSQESVTEQDSKDSTYSLSSTLTLSK TSGGTAALGCLVKDYFPEPVTVSWNSGALT
    ADYEKHKVYACEVTHQGLSSPVTKSFNRGE SGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    C (SEQ ID NO: 95) TQTYICNVNHKPSNTKVDKKVEPKCEF
     (SEQ ID NO: 96)
    H5L1
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKE TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    IVLTQSPGTLSLSPGERATLSCRASQSVSS VSASDDDDKLVQPGGSLRLSCAGSGFTFSS
    SYLAWYQQKPGQAPRLLIYGASSRATGIPD YVMHWLRQAPGKGLEWVSVIGTGGVTHYAD
    RFSGSGSGTDFTLTISRLEPEDFAVYYCQQ SVKGRFTISRDNAKNSLYLQMNSLRAEDTA
    YSSSLTFGGGTKVEIKRTVAAPSVFIFPPS VYYCARWGYYGSGSYENDAFDIWGQGTMVT
    DEQLKSGTASVVCLLNNFYPREAKVQWKVD VSSASTKGPSVFPLAPSSKSTSGGTAALGC
    NALQSGNSQESVTEQDSKDSTYSLSSTLTL LVKDYFPEPVTVSWNSGALTSGVHTFPAVL
    SKADYEKHKVYACEVTHQGLSSPVTKSFNR QSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    GEC (SEQ ID NO: 97) KPSNTKVDKKVEPKCEF (SEQ ID NO: 98)
    H5L4
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKL TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    TQSPGTLSLSPGERATLSCRASQSVSSSYL VSASDDDDKLVQPGGSLRLSCAGSGFTFSS
    AWYQQKPGQAPRLLIYGASSRATGIPDRFS YVMHWLRQAPGKGLEWVSVIGTGGVTHYAD
    GSGSGTDFTLTISRLEPEDFAVYYCQQYSS SVKGRFTISRDNAKNSLYLQMNSLRAEDTA
    SLTFGGGTKVEIKRTVAAPSVFIFPPSDEQ VYYCARWGYYGSGSYENDAFDIWGQGTMVT
    LKSGTASVVCLLNNFYPREAKVQWKVDNAL VSSASTKGPSVFPLAPSSKSTSGGTAALGC
    QSGNSQESVTEQDSKDSTYSLSSTLTLSKA LVKDYFPEPVTVSWNSGALTSGVHTFPAVL
    DYEKHKVYACEVTHQGLSSPVTKSFNRGEC QSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    (SEQ ID NO: 99) KPSNTKVDKKVEPKCEF (SEQ ID NO: 100)
    H5L7
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKS TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    PGTLSLSPGERATLSCRASQSVSSSYLAWY VSASDDDDKLVQPGGSLRLSCAGSGFTFSS
    QQKPGQAPRLLIYGASSRATGIPDRFSGSG YVMHWLRQAPGKGLEWVSVIGTGGVTHYAD
    SGTDFTLTISRLEPEDFAVYYCQQYSSSLT SVKGRFTISRDNAKNSLYLQMNSLRAEDTA
    FGGGTKVEIKRTVAAPSVFIFPPSDEQLKS VYYCARWGYYGSGSYENDAFDIWGQGTMVT
    GTASVVCLLNNFYPREAKVQWKVDNALQSG VSSASTKGPSVFPLAPSSKSTSGGTAALGC
    NSQESVTEQDSKDSTYSLSSTLTLSKADYE LVKDYFPEPVTVSWNSGALTSGVHTFPAVL
    KHKVYACEVTHQGLSSPVTKSFNRGEC QSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    (SEQ ID NO: 101) KPSNTKVDKKVEPKCEF (SEQ ID NO: 102)
    H5L8
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGDDDDKSPG TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    TLSLSPGERATLSCRASQSVSSSYLAWYQQ VSASDDDDKLVQPGGSLRLSCAGSGFTFSS
    KPGQAPRLLIYGASSRATGIPDRFSGSGSG YVMHWLRQAPGKGLEWVSVIGTGGVTHYAD
    TDFTLTISRLEPEDFAVYYCQQYSSSLTFG SVKGRFTISRDNAKNSLYLQMNSLRAEDTA
    GGTKVEIKRTVAAPSVFIFPPSDEQLKSGT VYYCARWGYYGSGSYENDAFDIWGQGTMVT
    ASVVCLLNNFYPREAKVQWKVDNALQSGNS VSSASTKGPSVFPLAPSSKSTSGGTAALGC
    QESVTEQDSKDSTYSLSSTLTLSKADYEKH LVKDYFPEPVTVSWNSGALTSGVHTFPAVL
    KVYACEVTHQGLSSPVTKSFNRGEC QSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    (SEQ ID NO: 103) KPSNTKVDKKVEPKCEF (SEQ ID NO: 104)
    H6L1
    Light chain Heavy chain
    DIVLTQPHSVSASPGKTVTISCTRSSGSVA QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    SYYVQWYQQRPGSSPTTVIYEDNHRPSGVP DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    DRFSGSIDTSSNSASLTISGLKTEDEADYY AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    CQSYDSNNLVVFGGGTKLTVLGASDDDDKE TAVYYCARVLSLTDYYWYGMDVWGQGTLVT
    IVLTQSPGTLSLSPGERATLSCRASQSVSS VDDDDKLVQPGGSLRLSCAGSGFTFSSYVM
    SYLAWYQQKPGQAPRLLIYGASSRATGIPD HWLRQAPGKGLEWVSVIGTGGVTHYADSVK
    RFSGSGSGTDFTLTISRLEPEDFAVYYCQQ GRFTISRDNAKNSLYLQMNSLRAEDTAVYY
    YSSSLTFGGGTKVEIKRTVAAPSVFIFPPS CARWGYYGSGSYENDAFDIWGQGTMVTVSS
    DEQLKSGTASVVCLLNNFYPREAKVQWKVD ASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    NALQSGNSQESVTEQDSKDSTYSLSSTLTL DYFPEPVTVSWNSGALTSGVHTFPAVLQSS
    SKADYEKHKVYACEVTHQGLSSPVTKSFNR GLYSLSSVVTVPSSSLGTQTYICNVNHKPS
    GEC (SEQ ID NO: 105) NTKVDKKVEPKCEF (SEQ ID NO: 106)
  • TABLE 9
    PROTEASE-REGULATED ANTIBODIES (Type 4)
    H1L5a
    Heavy chain Heavy chain
    QVQLVESGGTLVQPGGSLRLSCAASGFSFT QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    DAWMSWVRQAPGKELEWVSSISGSGGSTYY DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    AGSVKGRFTISRDNSKNTLYLQMNSLRAED AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    TAVYYCARAAAAAAAAAAAAAAWGQGTLVT TAVYYCARAAAAAAAAAAAAAAWGQGTLVT
    VSASDDDDKEVQLVQSGGGLVQPGGSLRLS VSASDDDDKEVQLVQSGGGLVQPGGSLRLS
    CAGSGFTFSSYVMHWLRQAPGKGLEWVSVI CAGSGFTFSSYVMHWLRQAPGKGLEWVSVI
    GTGGVTHYADSVKGRFTISRDNAKNSLYLQ GTGGVTHYADSVKGRFTISRDNAKNSLYLQ
    MNSLRAEDTAVYYCARWGYYGSGSYENDAF MNSLRAEDTAVYYCARWGYYGSGSYENDAF
    DIWGQGTMVTVSSASTKGPSVFPLAPSSKS DIWGQGTMVTVSSASTKGPSVFPLAPSSKS
    TSGGTAALGCLVKDYFPEPVTVSWNSGALT TSGGTAALGCLVKDYFPEPVTVSWNSGALT
    SGVHTFPAVLQSSGLYSLSSVVTVPSSSLG SGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
    TQTYICNVNHKPSNTKVDKKVEPKCEF TQTYICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 107) (SEQ ID NO: 108)
    H2L1a
    Heavy chain Heavy chain
    QVQLVESGGTLVQPGGSLRLSCAASGFSFT QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    DAWMSWVRQAPGKELEWVSSISGSGGSTYY DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    AGSVKGRFTISRDNSKNTLYLQMNSLRAED AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    TAVYYCARAAAAAAAAAAAAAAWGQGTLVT TAVYYCARAAAAAAAAAAAAAAWGQGTLVT
    VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    GVTHYADSVKGRFTISRDNAKNSLYLQMNS GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    LRAEDTAVYYCARWGYYGSGSYENDAFDIW LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    GQGTMVTVSSASTKGPSVFPLAPSSKSTSG GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    GTAALGCLVKDYFPEPVTVSWNSGALTSGV GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKCEF YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 109) (SEQ ID NO: 110)
    H2L2a
    Heavy chain Heavy chain
    QVQLVESGGTLVQPGGSLRLSCAASGFSFT QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    DAWMSWVRQAPGKELEWVSSISGSGGSTYY DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    AGSVKGRFTISRDNSKNTLYLQMNSLRAED AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    TAVYYCARAAAAAAAAAAAAAAWGQGTLVT TAVYYCARAAAAAAAAAAAAAAWGQGTLVT
    VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    GVTHYADSVKGRFTISRDNAKNSLYLQMNS GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    LRAEDTAVYYCARWGYYGSGSYENDAFDIW LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    GQGTMVTVSSASTKGPSVFPLAPSSKSTSG GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    GTAALGCLVKDYFPEPVTVSWNSGALTSGV GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKCEF YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 111) (SEQ ID NO: 112 )
    H2L4a
    Heavy chain Heavy chain
    QVQLVESGGTLVQPGGSLRLSCAASGFSFT QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    DAWMSWVRQAPGKELEWVSSISGSGGSTYY DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    AGSVKGRFTISRDNSKNTLYLQMNSLRAED AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    TAVYYCARAAAAAAAAAAAAAAWGQGTLVT TAVYYCARAAAAAAAAAAAAAAWGQGTLVT
    VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    GVTHYADSVKGRFTISRDNAKNSLYLQMNS GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    LRAEDTAVYYCARWGYYGSGSYENDAFDIW LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    GQGTMVTVSSASTKGPSVFPLAPSSKSTSG GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    GTAALGCLVKDYFPEPVTVSWNSGALTSGV GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKCEF YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 113) (SEQ ID NO: 114)
    H2L5a
    Heavy chain Heavy chain
    QVQLVESGGTLVQPGGSLRLSCAASGFSFT QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    DAWMSWVRQAPGKELEWVSSISGSGGSTYY DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    AGSVKGRFTISRDNSKNTLYLQMNSLRAED AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    TAVYYCARAAAAAAAAAAAAAAWGQGTLVT TAVYYCARAAAAAAAAAAAAAAWGQGTLVT
    VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    GVTHYADSVKGRFTISRDNAKNSLYLQMNS GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    LRAEDTAVYYCARWGYYGSGSYENDAFDIW LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    GQGTMVTVSSASTKGPSVFPLAPSSKSTSG GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    GTAALGCLVKDYFPEPVTVSWNSGALTSGV GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKCEF YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 115) (SEQ ID NO: 116)
    H2L7a
    Heavy chain Heavy chain
    QVQLVESGGTLVQPGGSLRLSCAASGFSFT QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    DAWMSWVRQAPGKELEWVSSISGSGGSTYY DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    AGSVKGRFTISRDNSKNTLYLQMNSLRAED AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    TAVYYCARAAAAAAAAAAAAAAWGQGTLVT TAVYYCARAAAPAAAAAAAAAAWGQGTLVT
    VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    GVTHYADSVKGRFTISRDNAKNSLYLQMNS GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    LRAEDTAVYYCARWGYYGSGSYENDAFDIW LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    GQGTMVTVSSASTKGPSVFPLAPSSKSTSG GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    GTAALGCLVKDYFPEPVTVSWNSGALTSGV GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKCEF YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 117) (SEQ ID NO: 118)
    H2L8a
    Heavy chain Heavy chain
    QVQLVESGGTLVQPGGSLRLSCAASGFSFT QVQLVESGGTLVQPGGSLRLSCAASGFSFT
    DAWMSWVRQAPGKELEWVSSISGSGGSTYY DAWMSWVRQAPGKELEWVSSISGSGGSTYY
    AGSVKGRFTISRDNSKNTLYLQMNSLRAED AGSVKGRFTISRDNSKNTLYLQMNSLRAED
    TAvYYCARAAAAAAAAAAAAAAWGQGTLVT TAVYYCARAAAAAAAAAAAAAAWGQGTLVT
    VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG VDDDDKEVQLVQSGGGLVQPGGSLRLSCAG
    SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG SGFTFSSYVMHWLRQAPGKGLEWVSVIGTG
    GVTHYADSVKGRFTISRDNAKNSLYLQMNS GVTHYADSVKGRFTISRDNAKNSLYLQMNS
    LRAEDTAVYYCARWGYYGSGSYENDAFDIW LRAEDTAVYYCARWGYYGSGSYENDAFDIW
    GQGTMVTVSSASTKGPSVFPLAPSSKSTSG GQGTMVTVSSASTKGPSVFPLAPSSKSTSG
    GTAALGCLVKDYFPEPVTVSWNSGALTSGV GTAALGCLVKDYFPEPVTVSWNSGALTSGV
    HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT HTFPAVLQSSGLYSLSSVVTVPSSSLGTQT
    YICNVNHKPSNTKVDKKVEPKCEF YICNVNHKPSNTKVDKKVEPKCEF
    (SEQ ID NO: 119) (SEQ ID NO: 120)
    • Example 3: TF-Binding ELISA
  • Biotinylated TF (1 μg/ml) was added to streptavidin pre-coated 96-well plates (Pierce Chemical, Rockford, Ill.) and incubated for 1 hr. The plates were then washed (5×) with PBS containing 0.5% Tween-20. Samples and controls (serially diluted) were added to the wells and incubated for 1 hr, followed by washes (5×) with PBS containing 0.5% Tween-20. Horseradish peroxidase (HRP)-conjugated anti-human IgG or HRP-conjugated anti-human Fab were diluted in PBS (1:5000) and added to each well. Following a 1 hr incubation, the plates were washed again. Amplex Red (10 μg/ml) was added to each well, and the signal was read using a plate reader. The data was analyzed using Softmax (Molecular Devices, Sunnyvale, Calif.). Results are shown in FIG. 10.
    • Example 4: RG1-Binding ELISA
  • Ninety-six well plates were coated with RG1 (1 μg/ml) by overnight incubation, and the plates were then washed (5×) with PBS containing 0.5% Tween-20. Samples and controls (serially diluted) were added to the wells and incubated for 1 hr, followed by washes (5×) with PBS containing 0.5% Tween-20. Horserandish peroxidase (HRP)-conjugated anti-human IgG or HRP-conjugated anti-human Fab were diluted in PBS (1:5000) and added to each well. Following a 1 hr incubation, the plates were washed again. Amplex Red (10 μg/ml) was added to each well, and the signal was read using a plate reader. The data was analyzed using Softmax (Molecular Devices, Sunnyvale, Calif.). Results are shown in FIG. 11.
    • Example 5: Sandwich Antigen-Binding ELISA
  • The antigen binding activity of a bispecific protease-regulated antibody (illustrated in FIG. 2) was measured using a sandwich antigen-binding ELISA. This antibody binds two antigens, RG-1 and TF, and the linker contains cleavage sites for enterokinase (“EK”).
  • Ninety-six well plates were coated with RG1 (1 μg/ml) by overnight incubation. The plates were then washed five times with PBS containing 0.5% Tween-20. Antibody samples and controls were digested with 30 units of enterokinase for 16 hr at 37° C. (see Example 4). The antibody samples, with or without enterokinase digestion, were serially diluted and added to the wells of the ELISA plates. The samples were incubated for one hour, followed by washes (5×) with PBS containing 0.5% Tween-20. Biotinylated TF (0.1 μg/ml) was added to each well and incubated for one hour. Horseradish peroxidase (HRP)-conjugated streptavidin (1:10000 diluted) was then added to each well. Following a one-hour incubation, the plates were washed again. Amplex Red (10 μg/ml) was added to each well, and the signal was read using a plate reader. The data was analyzed using Sofimax® (Molecular Devices, Sunnyvale, Calif.). Parental antibodies 3E10, 19G9, and polyclonal human Fab were used as controls. The results are the average of duplicate wells (FIG. 12). The untreated bispecific protease-regulated antibody simultaneously binds to both TF and RG-1 (“Link1” and “Link2,” respectively). However, following enterokinase treatment, the binding to both antigens is greatly reduced (“Link1/EK” and “Link2/EK,” respectively).
  • The antigen binding activity of several examples of protease-regulated antibodies was also measured using this assay. For example, the antigen binding activity of protease-regulated antibodies 3E10-Type1-Fab and 19G9-Type1-Fab is shown in FIG. 13. The controls are designated 3E10-Reg-Fab, 19G9-Reg-Fab, and HuFab.
  • The antigen binding activity of Fab-like protease-regulated antibodies is demonstrated in FIG. 14. The activity of antibodies H1L 1, H1L4, H1L7, H4L7, and H5L5 (Type 2) was measured in the absence and presence of enterokinase. Parental antibodies 3E10, 19G9, and polyclonal human Fab were used as controls. Similarly, FIG. 15 shows the antigen binding activity of Fab-like protease-regulated antibodies H2L1, H2L2, and H2L8 (Type 3) and H3L1, H3L4, and H5L4 (Type 4).
    • Example 6. Enterokinase Digestion of Protease-Regulated Antibodies
  • Protease-regulated antibodies were digested with EnterokinaseMax™, the catalytic subunit of enterokinase (Invitrogen, Carlsbad, Calif.). The concentration of antibodies was adjusted to 1-5 μg/ml. A volume of antibody (100 μl) was mixed with 20 μl 10× EnterokinaseMax™ buffer and 75 μl sterile water in a tube. EnterokinaseMax™ (5 μl) was added to each sample and the samples were incubated at 37° C. for 16 hr. For the control group, a volume of water (5 μl) was used.
    • Example 7. Western Blots of Antibodies
  • Three detection antibodies were used to probe protease-regulated antibodies: anti-human kappa antibody, anti-human IgG(H+L), and anti-Myc tag antibodies. These detection antibodies were conjugated with horseradish peroxidase (HRP). Approximately 50 ng of antibody samples were mixed with loading buffer containing DTT (Invitrogen, Carlsbad, Calif.) and boiled for 5 min. The samples were then loaded onto a 12% Bis-Tris NuPAGE® gel (Invitrogen, Carlsbad, Calif.), separated, and transferred to nitrocellulose membranes. After blocking with 5% dry milk for 2 hr, the nitrocellulose membrane was incubated with a detection antibody for 1.5 hr. The membrane was then washed in PBS containing 0.5% Tween-20, and incubated with SuperSignal West Femto (Pierce Chemical, Rockford, Ill.), and expose to X-ray film for development. Results are shown in FIGS. 16-18.
    • Example 8: Subcutaneous Xenograft Cancer Model
  • Human mammary xenograft, MaTu cells are maintained as adherent cultures in RPMI supplemented with 10% FBS. Ncr nude mice (8-12 weeks of age) are inoculated subcutaneously in the right flank with 5×106 cells in 0.1 mL of 80% matrigel/20% HESS. When tumors reach an average size of ˜180 mg (6 days), treatment is initiated. Antibodies are administered i.v. once every four days (Q4D×3) at a dose of 10 mg/kg. Control mice are treated with PBS or an unconjugated monoclonal antibody. Daily examinations into the health status of each animal are conducted. Each experimental group consists of 10 mice and the dosing volume was 0.1 mL/10 g body weight. The length and width of each tumor is measured by using an electronic caliper 2-3 times per week and tumor weights (mg) are calculated based on the formula of [length (mm)×width (mm)2]/2. All data, including daily observations, obtained throughout the course of the study are documented. Tumor growth inhibition (TGI) is calculated as 1-T/C×100, where T=final tumor weights from a treated group, and C=final tumor weights from the control group. The data demonstrates the therapeutic utility of antibodies for the treatment of tumors.
  • Other embodiments of the invention will be apparent to the skilled in the art from a consideration of this specification or practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

Claims (13)

1-28. (canceled)
29. A protease regulated antibody comprising a protease cleavage site in a linker located between a variable domain and an N-terminal non-functional antibody domain,
wherein the protease regulated antibody can only bind an antigen following protease activation that allows removal of the N-terminal non-functional antibody domain.
30. The antibody of claim 29, wherein the antibody is of the Fab-like or IgG-like type.
31. The antibody of claim 29, wherein the protease cleavage sites are selected from the group consisting of SEQ ID NO: 1-32.
32. The antibody of claims 29, wherein said antibody is conjugated to a therapeutic or cytotoxic agent.
33. The antibody of claim 32, wherein said antibody is conjugated to an agent selected from the group consisting of monomethylauristatin-E (MMAE), aplidin, azaribine, anastrozole, azacytidine, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, 10-hydroxycamptothecin, carmustine, celebrex, chlorambucil, cisplatin, irinotecan (CPT-Il), SN-38, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, ethinyl estradiol, estramustine, etoposide, etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3′,5′-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, fluorouracil, fluoxymesterone, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, leucovorin, lomustine, mechlorethamine, medroprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, phenyl butyrate, prednisone, procarbazine, paclitaxel, pentostatin, PSI-341, semustine streptozocin, tamoxifen, taxanes, taxol, testosterone propionate, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, velcade, vinblastine, vinorelbine, vincristine, ricin, abrin, ribomiclease, onconase, rapLR1, DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.
34. A pharmaceutical composition comprising a therapeutically effective amount of an antibody of any of claims 29, in combination with a pharmaceutically acceptable carrier.
35. A pharmaceutical composition according to claim 34 in combination with one or more pharmaceutical agents.
36. Use of an antibody according to claims 29 in the manufacture of a medicament for the treatment of a disease selected from the group of diseases consisting of cancer, infectious diseases, and autoimmune diseases.
37. A medicament comprising an antibody of claim 29.
38. A medicament for the treatment of cancer, infectious diseases, and autoimmune diseases comprising an antibody of claim 29.
39. A kit comprising an antibody of claim 29.
40. The kit of claim 39, further comprising one or more selected from the group consisting of
solutions for suspending or fixing the cells,
detectable labels,
solutions for rendering a polypeptide susceptible to the binding of an antibody,
solutions for lysing cells, and
solutions for the purification of polypeptides.
US15/466,587 2007-08-15 2017-03-22 Monospecific and multispecific antibodies and method of use Abandoned US20170210825A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/466,587 US20170210825A1 (en) 2007-08-15 2017-03-22 Monospecific and multispecific antibodies and method of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95591307P 2007-08-15 2007-08-15
PCT/EP2008/006750 WO2009021754A2 (en) 2007-08-15 2008-08-16 Monospecific and multispecific antibodies and method of use
US67194210A 2010-02-22 2010-02-22
US15/466,587 US20170210825A1 (en) 2007-08-15 2017-03-22 Monospecific and multispecific antibodies and method of use

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2008/006750 Continuation WO2009021754A2 (en) 2007-08-15 2008-08-16 Monospecific and multispecific antibodies and method of use
US12/671,942 Continuation US9624309B2 (en) 2007-08-15 2008-08-16 Monospecific and multispecific antibodies and method of use

Publications (1)

Publication Number Publication Date
US20170210825A1 true US20170210825A1 (en) 2017-07-27

Family

ID=40110987

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/671,942 Expired - Fee Related US9624309B2 (en) 2007-08-15 2008-08-16 Monospecific and multispecific antibodies and method of use
US15/466,587 Abandoned US20170210825A1 (en) 2007-08-15 2017-03-22 Monospecific and multispecific antibodies and method of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/671,942 Expired - Fee Related US9624309B2 (en) 2007-08-15 2008-08-16 Monospecific and multispecific antibodies and method of use

Country Status (6)

Country Link
US (2) US9624309B2 (en)
EP (2) EP2532676B1 (en)
JP (2) JP5485152B2 (en)
CA (1) CA2696263C (en)
ES (1) ES2628395T3 (en)
WO (1) WO2009021754A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266574A (en) * 2012-03-30 2017-10-20 拜尔健康护理有限责任公司 The antibody of albumen enzyme adjustment

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021841A2 (en) 2005-08-10 2007-02-22 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
CN101679974B (en) 2007-03-27 2015-09-30 航道生物技术有限责任公司 Comprise construct and the library of antibody surrogate light chain sequences
US9624309B2 (en) 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
CN104004088B (en) 2007-09-26 2017-11-07 Ucb医药有限公司 dual specificity antibody fusions
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP5785490B2 (en) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド BCR complex-specific antibody and method of use thereof
MX2010011955A (en) * 2008-04-29 2011-01-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
WO2009137666A2 (en) * 2008-05-08 2009-11-12 The Trustees Of The University Of Pennsylvania Chemiluminescence enhanced detection
MX2010013239A (en) 2008-06-03 2011-02-24 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102149825B (en) 2008-07-08 2015-07-22 Abbvie公司 Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
CN102164965B (en) 2008-09-26 2016-03-30 Ucb医药有限公司 Biological product
WO2010065882A1 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
JP5501439B2 (en) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト Multispecific antibody comprising a full-length antibody and a single chain Fab fragment
BRPI1010297A2 (en) 2009-04-07 2017-06-06 Roche Glycart Ag trivalent bispecific antibodies.
BRPI1012195A2 (en) * 2009-05-01 2018-04-24 Abbott Lab double variable domain immunoglobulins and their uses
EP2430047B1 (en) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Neutralizing molecules to influenza viruses
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2475682B1 (en) * 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
ES2672121T3 (en) 2009-10-07 2018-06-12 Macrogenics, Inc. Polypeptides containing Fc region that have an enhanced effector function due to alterations in the degree of fucosylation, and methods for their use
JP2013507928A (en) * 2009-10-15 2013-03-07 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
PE20170779A1 (en) 2010-03-04 2017-07-04 Macrogenics Inc ANTIBODIES REACTIVE WITH B7-H3, IMMUNOLOGICALLY ACTIVE FRAGMENTS OF THE SAME AND USES OF THE SAME
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
RU2013110876A (en) 2010-08-24 2014-09-27 Рош Гликарт Аг ACTIVATED SPECIFIC ANTIBODIES
CA2807278A1 (en) * 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CN103260639A (en) 2010-08-26 2013-08-21 Abbvie公司 Dual variable domain immunoglobulins and uses thereof
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
RU2607038C2 (en) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Antigen-binding proteins
TWI588156B (en) * 2011-03-28 2017-06-21 賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
WO2013003652A1 (en) * 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
BR112014015851A2 (en) 2011-12-30 2019-09-24 Abbvie Inc double specific binding proteins directed against il-13 and / or il-17
CN104105711B (en) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 Single-chain antibody and other heteromultimerics
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CN104395339A (en) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
KR101963231B1 (en) * 2012-09-11 2019-03-28 삼성전자주식회사 Protein complex for preparing bispecific antibodies and method using thereof
KR20210111353A (en) 2012-11-01 2021-09-10 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
PE20160533A1 (en) 2013-03-14 2016-06-09 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAINST ANTITHROMBIN BETA FORMING COMPLEXES WITH HEPARIN
MX2015013166A (en) 2013-03-15 2015-12-11 Abbvie Inc Dual specific binding proteins directed against il-1 beta and il-17.
CA2906095A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
CA2913051C (en) * 2013-05-28 2023-09-05 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
BR112016006929A2 (en) 2013-10-11 2017-09-19 Hoffmann La Roche ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, METHODS OF PREPARING ANTIBODY, TREATMENT OF PATIENTS AND GENERATION OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF THE ANTIBODY
GB2519786A (en) * 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
PT3137595T (en) 2014-04-29 2019-06-19 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
RU2016151645A (en) 2014-07-01 2018-08-03 Пфайзер Инк. SPECIFIC HETERODIMERIC DIANTISTS AND THEIR APPLICATION
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
TWI750110B (en) 2014-07-21 2021-12-21 瑞士商諾華公司 Treatment of cancer using humanized anti- bcma chimeric antigen receptor
AU2015292755B2 (en) 2014-07-21 2020-11-12 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
HUE049218T2 (en) 2014-08-19 2020-10-28 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CR20170143A (en) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
ES2764111T3 (en) 2014-12-03 2020-06-02 Hoffmann La Roche Multispecific antibodies
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
CA2981096A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Tnf-alpha binding polypeptides
CA2981098A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
PL3280729T3 (en) 2015-04-08 2022-08-22 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (en) 2015-07-29 2021-06-28 Immutep Sas COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017025698A1 (en) * 2015-08-11 2017-02-16 Queen Mary University Of London Bispecific, cleavable antibodies
CN108289952B (en) 2015-11-19 2021-02-05 雷维托普有限公司 Functional antibody fragment complementation of a two-component system for redirected killing of unwanted cells
CN108495651A (en) 2015-12-17 2018-09-04 诺华股份有限公司 The antibody molecule and application thereof of anti-PD-1
JP2019502695A (en) 2015-12-17 2019-01-31 ノバルティス アーゲー Combination of antibody molecule against PD-1 and C-Met inhibitor and use thereof
ES2847155T3 (en) 2016-01-21 2021-08-02 Novartis Ag Multispecific molecules targeting CLL-1
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
UA127341C2 (en) 2016-04-15 2023-07-26 Мекроудженікс, Інк. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
KR20220133318A (en) 2016-04-15 2022-10-04 노파르티스 아게 Compositions and methods for selective protein expression
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
AU2017295886C1 (en) 2016-07-15 2024-05-16 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CN118021943A (en) 2016-07-28 2024-05-14 诺华股份有限公司 Combination therapy of chimeric antigen receptor and PD-1 inhibitor
CN110267677A (en) 2016-08-01 2019-09-20 诺华股份有限公司 Use the Chimeric antigen receptor treating cancer combined with former M2 macrophage molecule inhibitor
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
SG10201913823VA (en) 2016-10-07 2020-03-30 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CN117630386A (en) 2016-11-28 2024-03-01 中外制药株式会社 Polypeptides comprising an antigen binding domain and a transport moiety
CN110036034A (en) 2016-12-09 2019-07-19 西雅图遗传学公司 The bivalent antibody of coiled coil masking
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
KR20200022447A (en) 2017-06-27 2020-03-03 노파르티스 아게 Dosage regimens of anti-TIM-3 antibodies and uses thereof
SG10201913147WA (en) 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN110637395B (en) * 2017-07-18 2021-11-02 阿维科斯公司 Plate-to-plate contact bridge system
AU2018302283A1 (en) 2017-07-20 2020-02-06 Novartis Ag Dosage regimens of anti-LAG-3 antibodies and uses thereof
US11345757B2 (en) * 2017-07-31 2022-05-31 Trishula Therapeutics, Inc. Anti-CD39 antibodies
PE20212205A1 (en) 2017-09-08 2021-11-18 Maverick Therapeutics Inc RESTRICTED CONDITIONALLY ACTIVATED BINDING PROTEINS
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN109957026A (en) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 Covalent multi-specificity antibody
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
AU2019272575A1 (en) 2018-05-21 2020-12-10 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by NK cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019230866A1 (en) * 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising il-1r1 binding domain and carrying moiety
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TW202016139A (en) 2018-06-13 2020-05-01 瑞士商諾華公司 Bcma chimeric antigen receptors and uses thereof
BR112020026033A2 (en) 2018-06-19 2021-03-23 Atarga, Llc antibody molecules to complement component 5 and uses thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
EP4249513A3 (en) 2018-12-20 2023-12-20 Novartis AG Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
KR20210106437A (en) 2018-12-20 2021-08-30 노파르티스 아게 Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
MX2021009763A (en) 2019-02-15 2021-09-08 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof.
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
CN113950355A (en) 2019-03-29 2022-01-18 阿塔盖有限责任公司 Antibody molecules to FGF23 and uses thereof
CN114466864A (en) 2019-06-21 2022-05-10 索瑞索制药公司 Polypeptides
CN114514243A (en) 2019-06-21 2022-05-17 索瑞索制药公司 Polypeptides
BR112022007376A2 (en) 2019-10-21 2022-07-05 Novartis Ag COMBINATION THERAPIES WITH VENETOCLAX AND TIM-3 INHIBITORS
BR112022007179A2 (en) 2019-10-21 2022-08-23 Novartis Ag TIM-3 INHIBITORS AND USES THEREOF
CA3163104A1 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
JP2023507190A (en) 2019-12-20 2023-02-21 ノバルティス アーゲー Use of anti-TGFβ antibodies and checkpoint inhibitors to treat proliferative diseases
CN115298322A (en) 2020-01-17 2022-11-04 贝克顿迪金森公司 Methods and compositions for single cell secretogomics
CA3167413A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
MX2022010685A (en) 2020-02-27 2022-09-23 Novartis Ag Methods of making chimeric antigen receptor-expressing cells.
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
WO2022104061A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4745181A (en) 1986-10-06 1988-05-17 Ciba Corning Diagnostics Corp. Polysubstituted aryl acridinium esters
EP0318554B2 (en) * 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
KR0159908B1 (en) 1990-05-17 1999-02-18 에또오 다께또시 Metal chelate compound and optical recording medium prepared therefrom
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5395752A (en) 1993-03-19 1995-03-07 Ciba Corning Diagnostics Corp. Long emission wavelength chemiluminescent compounds and their use in test assays
WO2000068689A1 (en) * 1999-05-10 2000-11-16 Prolinx Inc. Cell separation device and methods for use
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
CA2411967A1 (en) * 2000-06-09 2001-12-20 The Government Of The United States Of America, As Represented By The Se Cretary Of The Departent Of Health And Human Services Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
AUPR729801A0 (en) * 2001-08-27 2001-09-20 Nucleics Pty Ltd A method of sequestering and/or purifying a polypeptide
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2005035753A1 (en) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20060252096A1 (en) * 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
KR20140053410A (en) * 2005-08-19 2014-05-07 아보트 러보러터리즈 Dual variable domain immunoglobulin and uses thereof
US9624309B2 (en) 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266574A (en) * 2012-03-30 2017-10-20 拜尔健康护理有限责任公司 The antibody of albumen enzyme adjustment

Also Published As

Publication number Publication date
JP2014129374A (en) 2014-07-10
US20110229476A1 (en) 2011-09-22
JP5863201B2 (en) 2016-02-16
EP2532676A1 (en) 2012-12-12
EP2178914A2 (en) 2010-04-28
JP2010535832A (en) 2010-11-25
ES2628395T3 (en) 2017-08-02
CA2696263C (en) 2017-06-13
EP2532676B1 (en) 2017-03-22
JP5485152B2 (en) 2014-05-07
CA2696263A1 (en) 2009-02-19
US9624309B2 (en) 2017-04-18
WO2009021754A2 (en) 2009-02-19
WO2009021754A3 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
US20170210825A1 (en) Monospecific and multispecific antibodies and method of use
US11802158B2 (en) Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
US8168758B2 (en) Anti-MN antibodies and methods of using same
AU2010238723A1 (en) Anti-human ROR1 antibodies
WO2017023780A1 (en) Antibody-drug conjugates for targeting cd56-positive tumors
WO2016022939A1 (en) Human monoclonal antibodies specific for 5t4 and methods of their use
EP1720569B1 (en) Target for b-cell disorders
Elter et al. Protease-activation of fc-masked therapeutic antibodies to alleviate off-tumor cytotoxicity
US20200277396A1 (en) Treatment Method
CN114641503A (en) anti-CD 371 antibodies and uses thereof
Büyükköroğlu et al. Engineering monoclonal antibodies: Production and applications
CN112979790B (en) Antibodies and use in detecting novel coronaviruses
AU2016200917A1 (en) Anti-MN antibodies and methods of using same
Wei et al. Expression and characterisation of recombinant human CD48 and isolation of a human anti‐CD48 monoclonal antibody by phage display
WO2021141996A1 (en) Single- and multi-chain polypeptides that bind specifically to cd3 epsilon
CN115368457A (en) anti-TIGIT antibodies and uses thereof
AU2012251927A1 (en) Anti-MN antibodies and methods of using same

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION